Clinical trial register · China

Clinical Trials in China

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 07 Nov 2026, 03:17 UTC

19187

Studies in scope

all four open statuses

11790

Recruiting now

open to new participants

2028

Lead sponsors

across recruiting studies

Top sites

Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343

Trials in this register

Status

Study

Lead sponsor

Phase

Enrol

Chinese sites

Start

Active, closed

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

NCT06382142Triple-Negative Breast Cancer

DrugsEribulin·Vinorelbine·Iza-bren·Capecitabine

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3

418

Shanghai

2024-06-21

Recruiting

Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer

NCT06468215Carcinoma, Endometrioid, Fertility Preservation

Peking University People's Hospital

Not applicable

Beijing

2024-06-21

Recruiting

A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

NCT06483282Small Cell Lung Cancer Limited Stage

DrugsApatinib Mesylate·Adebrelimab·Etoposide·Carboplatin

Jin Ying

Phase 2

Hangzhou

2024-06-21

Not yet open

A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.

NCT06369935Relapsed/Refractory Multiple Myeloma

DrugEquecabtagene Autoleucel

Peking University People's Hospital

Observational

260

Beijing

2024-06-20

Recruiting

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

NCT06454968Marginal Zone Lymphoma

Peking Union Medical College Hospital

Phase 2

Beijing

2024-06-20

Recruiting

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer

DrugsSacituzumab tirumotecan·Fluorouracil·Leucovorin·Adrucil

Merck Sharp & Dohme LLC

Phase 1/2

220

Beijing, Fuzhou, Wuhan, Changsha, Shanghai, Chengdu

2024-06-20

Active, closed

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

NCT06313970Pancreatic Cancer

DrugsNab-paclitaxel·Lenvatinib·Gemcitabine·Bevacizumab

Fudan University

Phase 2

Shanghai

2024-06-20

Recruiting

Adebrelimab + Apatinib in SCLC Maintenance Therapy

NCT06475209SCLC

DrugsApatinib·Adebrelimab

Tang-Du Hospital

Phase 2

Xi'an

2024-06-20

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

Beijing, Chongqing, Dongguan, Guangzhou, Hangzhou, Hengyang, Jining, Nanjing

2024-06-20

Recruiting

Transcutaneous Auricular Vagus Nerve Stimulation Prevents Postoperative Delirium in Elderly Patients

NCT06421077Vagus Nerve Stimulation

Beijing Tiantan Hospital

Not applicable

1,776

Beijing

2024-06-20

Not yet open

Clinical Research on the Application of Single-channel Uterine Fibroid Morcellation System in Laparoscopic Myomectomy

NCT06442605Leiomyoma, Uterine

First People's Hospital of Hangzhou

Not applicable

Hangzhou

2024-06-20

Recruiting

The Impact of Lifestyle Intervention on Weight and Fertility in Obese Males

NCT06339840Obesity, Weight Loss, Male Fertility, Artificial Insemination

Third Affiliated Hospital of Zhengzhou University

Not applicable

Zhengzhou

2024-06-20

Recruiting

JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

NCT06514768B-cell Acute Lymphoblastic Leukemia (B-ALL)

DrugJY231

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Early Phase 1

Kunming

2024-06-20

Recruiting

Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer

NCT06791083Gastric Cancer

DrugsEnvafolimab·Fruquintinib

First Affiliated Hospital of Fujian Medical University

Phase 2

Fuzhou

2024-06-20

Recruiting

The Peripheral Blood Multi-Omics Study on Sleep Loss

NCT06492109Sleep Deprivation, Aging, Alzheimer Disease, Healthy Lifestyle

First Affiliated Hospital of Zhejiang University

Not applicable

Hangzhou

2024-06-20

Recruiting

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma

NCT06464861Primary Mediastinal B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma( DLBCL)

Second Affiliated Hospital, Zhejiang University, School of Medicine

Phase 1

Hangzhou

2024-06-20

Recruiting

TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination

NCT06478537Immune Thrombocytopenia

DrugsHetrombopag Olamine·Hetrombopag·Aspirin

Peking Union Medical College Hospital

Phase 2

Beijing

2024-06-20

Active, closed

A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)

NCT06433531Generalized Pustular Psoriasis

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 1

Beijing, Guangzhou, Shijiazhuang, Shenyang, Chengdu, Hangzhou

2024-06-19

Recruiting

A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBC

NCT06598046Metastatic Breast Cancer

Henan Cancer Hospital

Phase 2

Zhengzhou

2024-06-19

Recruiting

RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients

NCT06341400Bladder Cancer, Muscle-Invasive Bladder Carcinoma

Zhujiang Hospital

Phase 1/2

Guangzhou

2024-06-19

Recruiting

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

NCT06484556Tumor, Solid

DrugsNW-301D·NW-301V

Tao Zhang

Phase 1

Wuhan

2024-06-19

Recruiting

Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)

NCT06452147Anesthesia, Hip Fractures, Dementia, Cognitive Impairment

DrugsBupivacaine Liposome·Lidocaine

Second Affiliated Hospital of Wenzhou Medical University

Not applicable

1,860

Dongyang, Hangzhou, Jinhua, Lishui, Ningbo, Quzhou, Taizhou, Wenling

2024-06-19

Recruiting

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

NCT06341335Gastric and Gastroesophageal Junction Adenocarcinoma

DrugsPulocimab·Cadonilimab·Paclitaxel

Akeso

Phase 3

506

Beijing

2024-06-19

Recruiting

Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma

NCT06470217Locally Advanced Head and Neck Squamous Cell Carcinoma

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 2

116

Shanghai

2024-06-19

Recruiting

A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors

NCT06368921Solid Tumor

DrugVRT106

Guangzhou Virotech Pharmaceutical Co., Ltd.

Phase 1

Guangzhou, Zhengzhou, Jinan

2024-06-19

Not yet open

Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction

NCT06469060Esophageal Cancer

Shanghai Chest Hospital

Phase 2

Shanghai

2024-06-19

Recruiting

Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.

NCT06452602Esophageal Cancer

DrugConcurrent chemoradiotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase 2

Tianjin

2024-06-19

Recruiting

A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus

NCT06106906Systemic Lupus Erythematosus

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1/2

Wuhan

2024-06-19

Active, closed

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

NCT06445400HER2-positive Breast Cancer

DrugsT-Bren·Pertuzumab·Docetaxel

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2

Guangzhou

2024-06-19

Active, closed

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129Large B-cell Lymphoma

DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone

Celgene

Phase 3

850

Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou

2024-06-19

Recruiting

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors

NCT06468358Solid Tumor

DrugsLB4330·LB1410

L & L Bio Co., Ltd., Ningbo, China

Phase 1/2

194

Shanghai

2024-06-19

Recruiting

GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma

NCT06455410Nasopharyngeal Carcinoma

DrugsConcurrent chemoradiotherapy·CCRT·Adebrelimab

Sun Yat-sen University

Phase 2

216

Foshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen, Zhangjiang

2024-06-18

Recruiting

A Long-term Follow-up Study in Participants Who Received CS-101

NCT06479616Beta-Thalassemia

Children's Hospital of Fudan University

Not applicable

Shanghai

2024-06-18

Recruiting

Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors

NCT07584954Solid Tumor Cancer, Solid Tumor Cancer Treatment With Immunotherapy

Jun Zhou

Phase 1

Fuzhou, Anyang, Jinan, Shanghai

2024-06-18

Recruiting

AMT-676 in Patients With Advanced Solid Tumors

NCT06400485Advanced Solid Tumors

DrugAMT-676

Multitude Therapeutics Inc.

Early Phase 1

Fuzhou, Guangzhou, Shanghai, Chengdu, Hangzhou

2024-06-18

Recruiting

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies

NCT06316856T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies

Beijing GoBroad Hospital

Phase 1/2

Beijing, Shanghai, Chengdu

2024-06-18

Recruiting

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma

NCT06471257Asthma

AstraZeneca

Phase 3

1,000

Baotou, Beijing, Changchun, Changsha, Chengdu, Chizhou, Chongqing, Dazhou

2024-06-17

Active, closed

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

NCT05562947Neovascular Age-related Macular Degeneration, nAMD

DrugRanibizumab

Hoffmann-La Roche

Phase 3

Beijing, Chengdu, Guangzhou, Harbin, Qingdao, Shanghai, Shenyang, Taiyuan

2024-06-17

Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

6,712

Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Dalian

2024-06-17

Recruiting

the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children

NCT05911893Malnutrition, Child, Malnourishment, Nutritional Deficiency, Undernutrition

Children's Hospital of Chongqing Medical University

Not applicable

200

Hefei, Beijing, Jilin City, Chongqing, Guangzhou, Guiyang, Changsha, Nanjing

2024-06-17

Recruiting

A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

NCT06378593Solid Tumors With FGFR2 Alterations, Adult

Drug3HP-2827

3H (Suzhou) Pharmaceuticals Co., Ltd.

Phase 1/2

130

Beijing, Shanghai

2024-06-17

Recruiting

Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

NCT06427239Pancreatic Cancer

DrugsHRS-4642·SHR-8068·Adebrelimab·Bevacizumab

Fudan University

Phase 1/2

130

Shanghai

2024-06-17

Recruiting

Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)

NCT06385730Esophageal Cancer

DrugNeoadjuvant anti-PD-1

Shanghai Chest Hospital

Phase 2

Shanghai

2024-06-17

Recruiting

Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia

NCT06537115Sarcopenia

Zhejiang Provincial People's Hospital

Phase 4

450

Hangzhou, Huzhou, Taizhou, Zhoushan

2024-06-16

Recruiting

Endovascular Treatment for eXtra-Large Ischemic Stroke

NCT06388148Stroke, Acute Ischemic

Zhongming Qiu

Not applicable

286

Hengyang, Xiangtan

2024-06-16

Active, closed

Mesenteric Lymph Node Metastasis and Nutritional Status After Bowel Resection for Ovarian Cancer

NCT06527001Progression-Free Survival, Overall Survival, Nutrition Aspect of Cancer

Anhui Provincial Hospital

Observational

300

Hefei

2024-06-16

Recruiting

Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD

NCT06418477Monoclonal Gammopathy of Renal Significance

Peking University People's Hospital

Phase 2

Beijing, Guangzhou

2024-06-15

Recruiting

Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis

NCT06225752Ischemic Stroke, TIA

DrugProbucol

First Affiliated Hospital of Wannan Medical College

Phase 3

5,452

Wuhu

2024-06-15

Recruiting

Nursing Interventions for Alzheimer's Patients During PET/CT Imaging

NCT06784830Alzheimer's Disease

Sichuan Provincial People's Hospital

Not applicable

200

Chengdu

2024-06-15

Recruiting

Efficacy and Safety of Photobiomodulation Therapy in Patients With Mild Cognitive Impairment and Mild Alzheimer's Disease

NCT07835399Mild Cognitive Impairment (MCI), Mild Alzheimer Disease, Dementia

Jun Xu

Not applicable

Beijing

2024-06-15

Not yet open

Phase IV Study of Concomitant Administration of the sIPV and HepA

NCT06460545Polio, Hepatitis A

DrugSIPV

Institute of Medical Biology, Chinese Academy of Medical Sciences

Phase 4

2,000

Chongqing

2024-06-15

Recruiting

The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression

NCT06708156Myopia, Myopia Progression

DrugAtropine sulfate eye

Oupushifang Pharmaceutical Technology Co., Ltd.

Phase 3

606

Hefei, Xuancheng, Lanzhou, Liuzhou, Nanning, Guiyang, Zunyi, Daqing

2024-06-15

Not yet open

F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus

NCT06468683Lupus Erythematosis

Shanghai Simnova Biotechnology Co.,Ltd.

Phase 1

Shanghai

2024-06-15

Recruiting

Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer

NCT06454448Adebrelimab (SHR-1316), Decitabine, Metastatic Pancreatic Cancer

DrugsDecitabine·Adebrelimab

Tianjin Medical University Cancer Institute and Hospital

Phase 1/2

Tianjin

2024-06-15

Recruiting

Organ Dysfunction Change in Acute Necrotizing Pancreatitis Patients With Sepsis After Open Necrosectomy

NCT06380842Necrotizing Pancreatitis

Chunling Jiang

Observational

200

Chengdu

2024-06-15

Recruiting

A Study of IBI363 in Subjects With Advanced Malignancies

NCT06468098Advanced Malignancies

DrugLenvatinib

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1

556

Shanghai

2024-06-15

Recruiting

Application of HFNC for the Prevention of Hypoxemia During Perioperative Anesthetic-induced Intubation in Children: A Randomized Controlled Clinical Trial

NCT06425406High-flow Nasal Cannula, Children, Pre-oxygenation

Henan Provincial People's Hospital

Not applicable

Zhengzhou

2024-06-15

Recruiting

The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.

NCT06597526Peritoneal Metastasis, Gastric Cancer

Ruijin Hospital

Observational

Shanghai

2024-06-15

Recruiting

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

NCT06378242High-risk Non-muscle Invasive Bladder Cancer

DrugDisitamab Vedotin

RemeGen Co., Ltd.

Phase 1/2

Guangzhou, Wuhan, Changsha, Nanjing, Chengdu, Tianjin

2024-06-14

Recruiting

Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease

NCT05831085Coronary Artery Stenosis

Duk-Woo Park, MD

Not applicable

1,500

Beijing, Hanzhou

2024-06-14

Recruiting

Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

NCT06461910Gastric Cancer, Esophagogastric Junction Adenocarcinoma

DrugsThymalfasin·Tegafur·Serplulimab·Oxaliplatin

Zekuan Xu

Phase 2

Nanjing

2024-06-14

Recruiting

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

NCT06508983Relapsed/Refractory Multiple Myeloma

DrugsSG301·Pomalidomide·Dexamethasone

Hangzhou Sumgen Biotech Co., Ltd.

Phase 3

360

Beijing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Suzhou, Taiyuan, Xi’an

2024-06-14

Recruiting

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06574568Relapsed or Refractory Multiple Myeloma

DrugYKST02

Excyte Biopharma Ltd

Phase 1

Beijing, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Dalian, Jinan

2024-06-14

Recruiting

A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis

NCT05303285Ankylosing Spondylitis (AS)

DrugSecukinumab

Tongji Hospital

Phase 4

100

Wuhan

2024-06-14

Recruiting

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

NCT06532539Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis

DrugsPaclitaxel and Cisplatin)·Cadonilimab

Shandong Cancer Hospital and Institute

Phase 2

Jinan

2024-06-13

Recruiting

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

NCT06437509Extensive-stage Small-cell Lung Cancer

DrugIza-bren

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2

Shanghai

2024-06-13

Recruiting

China Healthy Aging Cohort Study

NCT06472674Age Problem, Disability, Dementia, Death

Xuanwu Hospital, Beijing

Observational

6,780

Beijing

2024-06-13

Recruiting

The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy

NCT06461377Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)

DrugSemaglutide

The First Affiliated Hospital with Nanjing Medical University

Phase 4

Nanjing

2024-06-13

Active, closed

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

NCT07371910Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer

DrugApatinib

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

200

Guangzhou

2024-06-12

Recruiting

A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging

NCT06769893RCC, Renal Cell Cancer

Xijing Hospital

Not applicable

Xi'an, China

2024-06-12

Recruiting

Spinal Versus General Anesthesia on Postoperative Pulmonary Complications

NCT06425627Pulmonary Complication, Anesthesia, Hip Fractures

Tongji Hospital

Not applicable

Wuhan

2024-06-12

Recruiting

Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis

NCT06414135Systemic Sclerosis

DrugRelma-cel

Liangjing Lu

Phase 1

Shanghai

2024-06-12

Recruiting

Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression

NCT06375564Refractory Solid Tumor

The First Affiliated Hospital of Xiamen University

Phase 1

Xiamen

2024-06-12

Recruiting

Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

NCT06813365Nonsmall-cell Lung Cancer

DrugDZD6008

Dizal Pharmaceuticals

Phase 1

300

Beijing

2024-06-12

Recruiting

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

NCT06255392Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer

DrugsPaclitaxel-albumin·Apatinib Mesylate·Fluzoparib·Eribulin

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

200

Guangzhou

2024-06-12

Recruiting

Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.

NCT06655662Β-thalassemia

Shenzhen Hemogen

Phase 1

Guangxi, Shenzhen

2024-06-12

Recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

NCT06409702Newly Diagnosed, High Risk, MRD, Multiple Myeloma

DrugsDarzalex·Carfilzomib·Daratumumab·Lenalidomide

The First Affiliated Hospital of Soochow University

Phase 4

Suzhou

2024-06-12

Active, closed

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

NCT06447623Advanced Breast Cancer, HR+/HER2- Breast Cancer

DrugApatinib

Fudan University

Phase 3

184

Shanghai

2024-06-11

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754Non-small Cell Lung Cancer (NSCLC)

DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

550

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin

2024-06-11

Active, closed

PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

NCT06419621Triple Negative Breast Cancer(TNBC)

DrugsPumitamig·Nab-paclitaxel

Biotheus Inc.

Phase 3

392

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Foshan, Guangzhou

2024-06-11

Recruiting

Exploring the Characteristics of Epileptogenic Foci in Drug-Resistant Epilepsy Based on Multimodal Imaging Technology

NCT06557720Drug Resistant Epilepsy, Magnetic Resonance Imaging, Electroencephalogram (EEG)

Xijing Hospital

Observational

Xi'an

2024-06-11

Recruiting

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

NCT06389292Acute Myeloid Leukemia

DrugsLisaftoclax·Azacitidine

Ascentage Pharma Group Inc.

Phase 3

486

Tianjin, Hangzhou

2024-06-11

Recruiting

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

NCT06611813HR+/HER2- Breast Cancer

DrugToripalimab

First Affiliated Hospital of Zhejiang University

Phase 2

Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Shanghai, Ürümqi, Xi'an

2024-06-11

Recruiting

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

NCT06398444Advanced Neuroendocrine Neoplasm

DrugLutetium[177Lu] Oxodotreotide

Sinotau Pharmaceutical Group

Phase 2/3

Shanghai

2024-06-11

Recruiting

Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL

NCT06481241Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult

DrugVenetoclax

Institute of Hematology & Blood Diseases Hospital, China

Not applicable

Tianjin

2024-06-10

Recruiting

Feasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric Cancer

NCT05892289Stomach Neoplasms

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not applicable

Guangzhou

2024-06-10

Active, closed

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

NCT06472076Lung Cancer, Non-Small Cell

DrugsBelrestotug·Dostarlimab·Pembrolizumab

GlaxoSmithKline

Phase 3

Chengdu, Hangzhou, Hefei, Nanjing, Shanghai

2024-06-10

Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143Non-small Cell Lung Cancer, NSCLC

DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

851

Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan

2024-06-10

Recruiting

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

NCT06482801Liver Cancer, Antibody

DrugsDurvalumab, idarubicin, bevacizumab·Ipilimumab·Pembrolizumab

Second Affiliated Hospital of Guangzhou Medical University

Phase 2

Guangzhou

2024-06-10

Recruiting

Personalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability

NCT06430554Respiratory Distress Syndrome, Positive-Pressure Respiration, Mechanical Ventilation

Zhongda Hospital

Observational

Nanjing

2024-06-08

Active, closed

A Retrospective Cohort Study on the Non-Surgical Treatment of Periapical Inflammatory Lesions With Vitapex Paste

NCT07907367Periapical Periodontitis, Periapical Abscess, Periapical Radiolucency

The Affiliated Hospital of Jinggangshan University

Observational

Ji’an

2024-06-08

Recruiting

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

NCT06437522Head and Neck Squamous Cell Carcinoma

DrugIza-bren

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2

Shanghai

2024-06-07

Recruiting

The Effect and Mechanism of Xiqing Regulating Intestinal Homeostasis on Drug Efficacy of Chronic Kidney Disease

NCT07182942CKD, Drug Effect

DrugXiqing

Chujin Cao

Phase 4

120

Wuhan

2024-06-07

Recruiting

Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis

NCT06976177Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

DrugMT1013

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Phase 2

310

Hangzhou

2024-06-07

Active, closed

A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06448312Non-Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pembrolizumab

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3

406

Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Dongguan

2024-06-07

Recruiting

A Substudy of the Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery

NCT06881498Bone Tumor, Acute Normovolemic Hemodilution, Goal-Directed Fluid Therapy

Second Affiliated Hospital, Zhejiang University, School of Medicine

Not applicable

Hangzhou

2024-06-07

Recruiting

The Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery

NCT06459141Acute Normovolemic Hemodilution, Bone Tumor, Goal-Directed Fluid Therapy, Transfusion

Second Affiliated Hospital, Zhejiang University, School of Medicine

Not applicable

150

Hangzhou

2024-06-07

Recruiting

Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen

NCT06456892Rhabdomyosarcoma, Pediatric Cancer

DrugPucotenlimab

Sun Yat-sen University

Phase 1/2

Guangzhou

2024-06-06

Active, closed

Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer

NCT06458413Breast Cancer Recurrent

DrugsUtidelone·Capecitabine

Min Yan, MD

Phase 2

Zhengzhou

2024-06-06

Recruiting

Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort

NCT06399185Urinary Catheter, Catheter-related Bladder Discomfort, Dexmedetomidine, Esketamine

DrugsEsketamine·Dexmedetomidine

Peking University First Hospital

Phase 4

1,740

Beijing, Shenzhen

2024-06-06

Active, closed

Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma

NCT06885814Esophageal Squamous Cell Carcinoma

Nanfang Hospital, Southern Medical University

Phase 2

Guangzhou

2024-06-06

Recruiting

A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour

NCT06383871Advanced Malignant Tumour

Shandong Suncadia Medicine Co., Ltd.

Phase 1

233

Tianjin

2024-06-06

Recruiting

Multimodal Magnetic Resonance Imaging in Evaluation of Diabetic Kidney Disease

NCT06452862Diabetic Kidney Disease

Shengjing Hospital

Observational

150

Shenyang

2024-06-06

Recruiting

Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

NCT06407947Multiple Myeloma

Shanghai Changzheng Hospital

Early Phase 1

Shanghai

2024-06-06

Recruiting

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

NCT06425341Chronic Hepatitis B

DrugsHRS-5635·Peg-IFNα

Fujian Shengdi Pharmaceutical Co., Ltd.

Phase 2

369

Guangzhou

2024-06-06

Recruiting

Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children

NCT06440915Aspergillosis Invasive, Mucormycosis

DrugIsavuconazole

Shanghai Children's Medical Center

Not applicable

200

Shanghai

2024-06-06

Recruiting

Mobile Applet for Weight Management in Obese Heart Failure Patients

NCT06455878Heart Failure, Overweight and Obesity, Weight Loss, Heart Failure With Reduced Ejection Fraction

Heart Health Research Center

Not applicable

830

Beijing, Guangzhou, Langfang, Jixi, Luoyang, Shangqiu, Xinyang, Zhengzhou

2024-06-06

Recruiting

Anti-cancer DC Cell Vaccination to Treat Solid Tumors

NCT06477614Solid Tumor, Adult, DC

Second Affiliated Hospital of Guangzhou Medical University

Phase 1

Guanzhou

2024-06-05

Recruiting

A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese Population

NCT06724848COPD

AstraZeneca

Observational

850

Beijing, Changsha, Chengdu, Guangzhou, Hefei, Nanjing, Nanning, Shanghai

2024-06-05

Active, closed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

DrugsTarlatamab·Durvalumab

Amgen

Phase 3

563

Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Guilin, Nanning, Cangzhou

2024-06-05

Not yet open

Efficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer

NCT06453889Lung Cancer

Shanghai Chest Hospital

Not applicable

Shanghai

2024-06-05

Recruiting

Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma

NCT06528847Non-Small Cell Lung Cancer

DrugBenmelstobart

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2

Shanghai

2024-06-05

Recruiting

A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

NCT06277219Advanced Solid Tumor

Latticon Antibody Therapeutics, Inc

Phase 1/2

150

Jinan, Hangzhou

2024-06-05

Recruiting

Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia

NCT06450067B-cell Acute Lymphoblastic Leukemia

Juventas Cell Therapy Ltd.

Observational

200

Beijing, Guangzhou, Zhengzhou, Wuhan, Xuzhou, Jinan, Shanghai, Chengdu

2024-06-05

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou

2024-06-05

Recruiting

Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors

NCT06195293Solid Tumor, Adult

DrugNeoantigen polypeptide vaccine

Second Affiliated Hospital of Guangzhou Medical University

Phase 1

Guangzhou

2024-06-04

Recruiting

Impact of the Digital Multi-domain Cognitive Intervention in High-risk Populations for Dementia

NCT06442943Cognitive Dysfunction

Fujian Provincial Hospital

Not applicable

128

Fuzhou

2024-06-04

Recruiting

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

NCT06481228Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult

DrugsOlverembatinib·Venetoclax

Institute of Hematology & Blood Diseases Hospital, China

Not applicable

Tianjin

2024-06-04

Recruiting

A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries

NCT06539689Peripheral Arterial Disease, Stenosis, Dissection

FrontAce Scientific Co., Ltd

Not applicable

240

Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nantong, Shanghai

2024-06-04

Recruiting

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

NCT06459973Advanced Solid Tumors

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2

252

Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin, Anyang, Zhengzhou

2024-06-04

Active, closed

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

NCT06413745HER2 Expression / Amplification in Patients With Biliary Tract Cancer

DrugTrastuzumab Rezetecan

Jiangsu HengRui Medicine Co., Ltd.

Phase 2

Shanghai

2024-06-04

Recruiting

Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

NCT06192797Cholangiocarcinoma Non-resectable

DrugsPucotenlimab·Lenvatinib

Tongji Hospital

Phase 2

Wuhan

2024-06-04

Recruiting

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

NCT06439277Obesity, Weight Gain

DrugTirzepatide

Eli Lilly and Company

Phase 3

300

2024-06-03

Recruiting

Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.

NCT07169656Chronic Hepatitis b

DrugPeginterferon α-2b

The First Affiliated Hospital of Zhengzhou University

Observational

15,000

Anyang, Guangzhou, Hebi, Jiaozuo, Jiayuguan, Jinan, Jiyuan, Kaifeng

2024-06-03

Recruiting

Fractional Flow Reserve-guided Stenting Versus Medical Therapy in Atherosclerosis Renal Artery Stenosis

NCT06447740Renal Artery Stenosis Atherosclerotic, Secondary Hypertension Renal Arterial

DrugDopamine

Peking University First Hospital

Not applicable

200

Beijing

2024-06-03

Recruiting

Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation

NCT06275555Extracorporeal Membrane Oxygenation Complication

DrugsBivalirudin·Unfractionated heparin

Xiaotong Hou

Not applicable

154

Beijing

2024-06-03

Active, closed

Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application

NCT06729619Intracranial Infection, Central Infection

Xueyan Cui

Observational

200

Jinan

2024-06-03

Recruiting

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

NCT06157996Gastric Cancer

DrugTislelizumab

Nanfang Hospital, Southern Medical University

Phase 2

Guangzhou

2024-06-01

Not yet open

LCMD for Type 2 Diabetes Remission: Evaluation of Effectiveness and Exploration of Individual Differences

NCT06442150Type 2 Diabetes Mellitus in Obese, Type 2 Diabetes

Shanghai Municipal Hospital of Traditional Chinese Medicine

Not applicable

170

Shanghai

2024-06-01

Recruiting

Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma

NCT06413342Esophageal Cancer, Chemoradiotherapy, Sintilimab, Immunotherapy

DrugSintilimab

Zhejiang Cancer Hospital

Phase 2

191

Hangzhou

2024-06-01

Recruiting

Effectiveness of Endoluminal Treatment of Autologous Arteriovenous Endovascular Fistula Failure

NCT06493292Hemodialysis Access Failure

RenJi Hospital

Observational

180

Zhengzhou, Nanjing, Shanghai

2024-06-01

Not yet open

Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR

NCT06297772AML, Adult

DrugsBusulfan·Decitabine·Fludarabine

Ruijin Hospital

Phase 3

220

Shanghai

2024-06-01

Recruiting

Hemodynamic Study of In-Stent Stenosis(I) After Flow Diverter(F) Based on 3D-DSA(D) Combined With TCCD(T)

NCT06448949Hemodynamics;In-stent Stenosis;Transcranial Doppler;Intracranial Aneurysm;Flow Diverter; Prospective Cohort Study

Zhujiang Hospital

Observational

200

Guangzhou

2024-06-01

Recruiting

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

NCT06420440HCC

DrugsLenvatinib·Tislelizumab

Chen Xiaoping

Phase 2

160

Xiangyang, Jinan

2024-06-01

Active, closed

Maternal Use of Antibiotics and the Risk of Congenital Malformations

NCT06770465Congenital Malformations

West China Hospital

Observational

850,000

Chengdu

2024-06-01

Recruiting

HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC

NCT06548529HER2 Positive or Suspicious Positive Tumors

Peking University Cancer Hospital & Institute

Not applicable

Beijing

2024-06-01

Recruiting

FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer

NCT06405113Gastric Cancer

Changzhou No.2 People's Hospital

Phase 2

198

Changzhou

2024-06-01

Not yet open

Washed Microbiota Transplantation for Allergic Rhinitis

NCT06372184Rhinitis, Allergic

DrugWashed Microbiota Transplantation

The Second Hospital of Nanjing Medical University

Not applicable

Nanjing

2024-06-01

Recruiting

Liposomal and Standard Bupivacaine in Thoracic Paravertebral Block for Post-Thoracoscopic Pain

NCT06165991Thoracic Paravertebral Block, Postoperative Analgesia, Thoracoscopic Lobectomy

DrugBupivacaine Hydrochloride

Yongtao Sun

Phase 4

496

Jinan

2024-06-01

Recruiting

Clinical Outcomes of Cardiovascular Disease

NCT06459934Cardiovascular Diseases, Heart Failure, Coronary Artery Disease

Xinjiang Medical University

Observational

30,000

Ürümqi

2024-06-01

Recruiting

Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke

NCT06170944Stroke, Ischemic

General Hospital of Shenyang Military Region

Not applicable

300

Shenyang

2024-06-01

Recruiting

Individualized ANH for Non-cardiac Surgery

NCT06399536Transfusion Related Complication, Hemodilution

West China Hospital

Not applicable

Chengdu

2024-06-01

Recruiting

Diagnostic Value of Deep Learning-Based Rapid MRI in Preoperative Evaluation of Acute Cholecystitis

NCT07551375Acute Cholecystitis

Peking Union Medical College Hospital

Observational

300

Beijing

2024-06-01

Not yet open

Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma

NCT06449846Hepatocellular Carcinoma Resectable, Surgery, Recurrence

Zhujiang Hospital

Observational

152

Foshan, Guangzhou, Guanzhou

2024-06-01

Recruiting

Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer

NCT06364371Predictive Cancer Model, Pathologic Complete Response

Sixth Affiliated Hospital, Sun Yat-sen University

Observational

106

Guangzhou

2024-06-01

Recruiting

Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study

NCT06650553Aplastic Anemias

Shanxi Bethune Hospital

Not applicable

110

Taiyuan

2024-06-01

Not yet open

A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy

NCT06422637Liquid Biopsy for Early Screening of Lung Cancer

The First Affiliated Hospital of Guangzhou Medical University

Not applicable

5,944

Guangzhou

2024-06-01

Recruiting

Resting Energy Expenditure and Substrate Consumption in Cardiac Arrest Patients Under Target Temperature Management

NCT06575101Targeted Temperature Management, Cardiac Arrest, Resting Energy Expenditure, Nutrition

Tang Ziren

Observational

Beijing

2024-06-01

Recruiting

Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer

NCT06889623NMIBC

Changhai Hospital

Not applicable

Shanghai

2024-06-01

Active, closed

Effect of Intraperitoneal Drain Placement on Postoperative Outcomes Following Laparoscopic Appendectomy in Adult Patients With Perforated Appendicitis

NCT06927765Perforated Appendicitis

The Affiliated Hospital of Qingdao University

Observational

500

Qingdao

2024-06-01

Recruiting

A Point-of-care Electrochemical-based Device for Rapid Detection of Fibrinogen on Type A Aortic Dissection Surgery

NCT06434389Hypofibrinogenemia

Second Affiliated Hospital, Zhejiang University, School of Medicine

Observational

150

Hangzhou

2024-06-01

By invitation

Artificial Intelligence in Detecting Cardiac Function

NCT06444425Heart Failure, Deep Learning

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Observational

685

Yiwu

2024-06-01

Not yet open

Effectiveness of Robotic Surgery for Right Colon Cancer

NCT06421974Colon Cancer, Robotic Surgery

Sir Run Run Shaw Hospital

Not applicable

610

Hanzhou

2024-06-01

Recruiting

Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.

NCT06393361Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma

DrugsDecitabine·Chidamide

Chinese PLA General Hospital

Phase 2

100

Beijing

2024-06-01

Recruiting

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer

NCT06881537Locally Recurrent Colorectal Cancer

DrugsTislelizumab·Capecitabine·Oxaliplatin·Bevacizumab

Shanghai Changzheng Hospital

Phase 2

Shanghai

2024-06-01

Active, closed

Establishment of Emergency Surgery Triage and Checklist Management System

NCT06501157Emergency Surgery, Triage, Checklist, Perioperative/Postoperative Complications

Peking Union Medical College Hospital

Observational

Beijing

2024-06-01

Recruiting

Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment

NCT06445881Non Small Cell Lung Cancer, Perioperative Complication

First Affiliated Hospital of Zhejiang University

Phase 2

Hangzhou

2024-06-01

Recruiting

Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes

NCT07131670Lung Cancer, Chemoradiotherapy, Patient-Reported Outcomes (PRO)

Qian Chu

Observational

100

Wuhan

2024-06-01

Recruiting

The Clinical Effect of Sugammadex Sodium (Domestic) for Antagonizing Neuromuscular Blockade After Thoracic Surgery

NCT06334562Neuromuscular Blockade

DrugNeostigmine

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Not applicable

Yiwu

2024-06-01

Recruiting

Clinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers

NCT06417086Alzheimer Disease, Cognitive Impairment

DrugDonepezil

ZhanYJ

Not applicable

176

Shanghai

2024-06-01

Active, closed

Exoskeleton Training on Balance Control and Turning in Ambulation in Individuals With Incomplete Spinal Cord Injury

NCT06971510Spinal Cord Injuries

Hong Kong Metropolitan University

Not applicable

Changzhou, Nanjing, Hong Kong

2024-06-01

By invitation

Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)

NCT06963060Gallbladder Cancer, Cholangiocarcinoma

Wei Gong

Phase 2

Shanghai

2024-06-01

Not yet open

Study on the Efficacy of Long-term Drainage of Subdural Effusion After Decompressive Craniectomy

NCT06391203Traumatic Brain Injury, Decompressive Craniectomy, Subdural Effusion

RenJi Hospital

Not applicable

160

Shanghai

2024-06-01

Recruiting

General Anesthesia vs Local Anesthesia for Endovascular Treatment in Patients With Unruptured Intracranial Aneurysm Using Flow Diverter

NCT06416657Intracranial Aneurysm

Ming Lv

Not applicable

188

Beijing

2024-06-01

Active, closed

SGLT2-inhibitors on PC-AKI

NCT06491953Impact of SGLT2-inhibitors on PC-AKI in ACS Patients Receiving Invasive Strategy

Shenyang Northern Hospital

Observational

3,600

Shenyang

2024-06-01

By invitation

Exploring the Application Value of New Magnetic Resonance Imaging Technologies in Non-invasive Quantitative Assessment of Graft Function After Liver Transplantation

NCT06994429Liver Transplantation, MRI, Graft Function

Zhen Li

Observational

1,000

Wuhan

2024-06-01

Recruiting

Ultrasound-guided Stellate Ganglion Block for Treatment of Chronic Migraine in Adult

NCT06322407Chronic Migraine

Beijing Tiantan Hospital

Not applicable

206

Beijing

2024-06-01

Recruiting

Oliceridine-Enhanced Analgesia and Recovery: A G-Protein Biased μ-Opioid Study

NCT06409689Postoperative Analgesia

DrugMorphine

Tongji Hospital

Not applicable

Wuhan

2024-06-01

Recruiting

Study on the Mechanism of ZhenQiFuZheng in the Treatment of Allergic Rhinitis Based on Intestinal Flora and Metabolites

NCT06427577Rhinitis, Allergic

The First Affiliated Hospital with Nanjing Medical University

Not applicable

Nanjing

2024-06-01

Not yet open

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

NCT06361030Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Ductal Adenocarcinoma, PDAC

DrugsSurufatinib·Nab-paclitaxel·Gemcitabine

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2

Wuhan

2024-06-01

Recruiting

Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma

NCT06961617Hepatocellular Carcinoma

Lion TCR Pte. Ltd.

Phase 1

Beijing

2024-06-01

Not yet open

Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

NCT06089369Hepatocellular Carcinoma

DrugSintilimab

Tongji Hospital

Phase 3

360

Wuhan

2024-06-01

Active, closed

Prediction of Detoxification Effect of Fat Emulsion Based on Drug Diffusion Law

NCT06926439Poisoning, Toxicokinetics, Lipid Emulsion

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Observational

Nanjing

2024-06-01

Recruiting

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

NCT06359275Pancreatic Cancer

DrugsNab-paclitaxel·Gemcitabine

Fudan University

Phase 2

Shanhai

2024-06-01

Recruiting

Factors Influencing Physiological Hyperopia in Children

NCT06498947Myopia Progression

Beijing Tongren Hospital

Observational

1,006

Beijing

2024-06-01

Recruiting

Nutrition Impact on Immunotherapy of Cancer

NCT06500234Nutrition Disorders, Immunotherapy, Cancer, Survival, Prosthesis

Qingdao Central Hospital

Phase 3

300

Qingdao

2024-06-01

Recruiting

Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

NCT06425120Coronary Heart Disease

DrugXuesaitong soft

China National Center for Cardiovascular Diseases

Phase 4

240

Beijing, Nantong

2024-06-01

Active, closed

Risk Stratification for Abdominal Emergency Surgery: a Cohort Study

NCT06501170Emergency Surgery

Peking Union Medical College Hospital

Observational

1,000

Beijing

2024-06-01

Not yet open

Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer

NCT06443671Rectal Cancer

DrugCapeox

Peking University Cancer Hospital & Institute

Phase 2/3

132

Beijing

2024-06-01

Recruiting

Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma

NCT06470256Advanced Hepatocellular Carcinoma

DrugsDurvalumab·Lenvatinib

Zhiyong Huang

Phase 1

Wuhan

2024-06-01

Not yet open

Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study

NCT06435702Prostate Cancer

Peking University Third Hospital

Observational

108

Beijing

2024-06-01

Active, closed

Subiculum Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis(SESTB)

NCT06436547Epilepsy, Drug Resistant

Xuanwu Hospital, Beijing

Not applicable

Beijing

2024-06-01

Recruiting

Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies

NCT06462248Lymphoma, Nonhodgkin, Leukemia, Lymphocytic

Chi Kong Li

Phase 2

Hong Kong

2024-06-01

Recruiting

Risk Factors for Microvascular Obstruction Post-Emergency PCI in AMI Patients

NCT07042321Acute Myocardial Infarction (AMI)

The Third Xiangya Hospital of Central South University

Observational

300

Changsha

2024-06-01

Recruiting

Combination of Toripalimab and JS004 Therapy for ccRCC

NCT06690697Clear Cell Renal Cell Carcinoma

DrugsTifcemalimab·Sorafenib·Axitinib·Toripalimab

Fudan University

Phase 2

Shanghai

2024-06-01

Not yet open

Patient Education in the Clinical Management of Pessary

NCT06432218Pelvic Organ Prolapse

Peking Union Medical College Hospital

Not applicable

280

Beijing

2024-06

Not yet open

Effect of Antibiotic Pretreatment on the Efficacy of WMT in the Treatment of Chronic Constipation

NCT06427863Chronic Constipation

DrugOrnidazole

Faming Zhang

Not applicable

Nanjing

2024-06

Not yet open

A Study on Probiotic Formula in Autistic Children

NCT06419530Autism Spectrum Disorder

Third Military Medical University

Not applicable

156

Chongqing

2024-06

Not yet open

Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC

NCT06465238NSCLC

DrugsSHR-A1921·SHR-A2009

Henan Cancer Hospital

Phase 2

Zhengzhou

2024-06

Recruiting

Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD

NCT06449833Type2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease

Zhujiang Hospital

Phase 4

100

Guangzhou

2024-06

Not yet open

Henagliflozin's Impact on Prediabetes Remission

NCT06448130PreDiabetes, Prediabetic State, Type 2 Diabetes, Glucose Metabolism Disorders

DrugHenagliflozin

Shandong Provincial Hospital

Phase 4

984

Chuzhou, Hefei, Fuzhou, Lanzhou, Foshan, Guangzhou, Guanzhou, Shenzhen

2024-06

Not yet open

Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer

NCT06454435Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsTeysuno·Sintilimab·Nab-paclitaxel

Tianjin Medical University Cancer Institute and Hospital

Phase 2

158

Tianjin

2024-06

Not yet open

Effect of Antibiotic Pretreatment on the Efficacy of WMT in the Treatment of Irritable Bowel Syndrome

NCT06437041Irritable Bowel Syndrome

DrugOrnidazole

Faming Zhang

Not applicable

Nanjing

2024-06

Active, closed

The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM

NCT06427252Gastric Cancer, Metastatic

DrugHipec

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2024-05-31

Not yet open

Reverse Drilling Technique in Improving Outcomes After Arthroscopic Anterior Cruciate Ligament Reconstruction

NCT05994872Anterior Cruciate Ligament Injuries

Second Affiliated Hospital, Zhejiang University, School of Medicine

Not applicable

216

Huzhou, Lishui, Meicheng, Ningbo, Shaoxing, Taizhou

2024-05-31

Recruiting

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

NCT06445803Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent

Rong Tao

Phase 1

Nanchang, Shanghai

2024-05-31

Recruiting

An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency

NCT07644832Hemophilia A, Hemophilia B, Factor VII Deficiency

DrugSR604

Shanghai RAAS Blood Products Co., Ltd.

Phase 1/2

Changsha, Hefei, Jinan, Lanzhou, Shanghai, Taiyuan, Tianjin, Xi'an

2024-05-31

Recruiting

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

NCT06594640Diffuse Large B-cell Lymphoma

DrugsMitoxantrone Hydrochloride Liposome·Vincrystine·Prednisolone·Rituximab

Institute of Hematology & Blood Diseases Hospital, China

Phase 1/2

108

Tianjin

2024-05-30

Recruiting

A Cohort Study in Newly Diagnosed MZL

NCT06449885Marginal Zone Lymphoma

Fudan University

Observational

2,500

Shanghai

2024-05-30

Recruiting

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors

NCT06390774Locally Advanced, Recurrent or Metastatic Malignancies

DrugSSGJ-705

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 1

180

Jinan

2024-05-30

Recruiting

Stapler Reinforcement Patches Compared to Standard Staplers in Gastrojejunostomy

NCT06464978Gastric Cancer, Gastrostomy, Anastomotic Leakage, Postoperative Complications

Nanchong Central Hospital

Not applicable

382

Nanchong

2024-05-30

Not yet open

Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation

NCT06426758Graves Disease, Graves' Disease in Remission, Epstein-Barr Virus

Xiao-Ming Mao

Observational

300

Nanjing

2024-05-30

Active, closed

Effect of Preoperative Individualized Education on Anxiety and Recovery.

NCT06419088Education

Fujian Medical University Union Hospital

Not applicable

156

Fuzhou

2024-05-30

Recruiting

Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

NCT06438627Nasopharyngeal Carcinoma

DrugCamrelizumab

XIANG YANQUN

Phase 3

164

Guangzhou

2024-05-30

Active, closed

A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors

NCT07131189Locally Advanced/Metastatic Solid Tumors

DrugFL115

Suzhou Forlong Biotechnology Co., Ltd

Phase 1

Beijing, Guangzhou, Jinan

2024-05-30

Recruiting

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

NCT06346912Acute Lymphoblastic Leukemia,B-Cell, Non-hodgkin Lymphoma,B Cell

Zhejiang University

Early Phase 1

Hangzhou

2024-05-30

Recruiting

[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients

NCT06419361Stimulator of Interferon Gene, Cancer, Positron Emission Tomography

First Affiliated Hospital of Chongqing Medical University

Early Phase 1

Chongqing

2024-05-30

Recruiting

Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases

NCT06520774Aortic Arch Aneurysm, Penetrating Aortic Ulcer

Lifetech Scientific (Shenzhen) Co., Ltd.

Not applicable

103

Beijing, Changsha, Chengdu, Fuzhou, Hanzhou, Kunming, Nanjing, Shanghai

2024-05-30

Recruiting

Exploring the Diagnostic Biomarkers of Cognitive Disorders in China

NCT06419101Biomarkers, Dementia

Cuibai Wei，Clinical Professor

Observational

3,000

Beijing

2024-05-30

Recruiting

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

NCT06363994Mantle Cell Lymphoma

DrugsOrelabrutinib·Bendamustine·Rituximab

InnoCare Pharma Inc.

Phase 3

476

Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian

2024-05-29

Recruiting

Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma

NCT06445088Nasopharyngeal Carcinoma

Sun Yat-sen University

Observational

908

Fuzhou, Guangzhou, Zhongshan, Nanning, Wuzhou

2024-05-29

Recruiting

SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

NCT06350006CLDN18.2-positive Advanced Solid Tumor

DrugsSHR-A1904·Folfox·Adebrelimab

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 1

924

Guangzhou

2024-05-29

Recruiting

Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases

NCT06428188Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus Acute, Sjogren's Syndrome

Essen Biotech

Phase 1/2

Beijing

2024-05-29

Recruiting

A Study of GC203 TIL in Advanced Malignant Solid Tumors

NCT06375187Solid Tumor, Gynecologic Cancer, Breast Cancer, Gastrointestinal Cancer

DrugEngineering Tumor Infiltrating Lymphocytes

Shanghai Juncell Therapeutics

Phase 1

Shanghai

2024-05-29

Recruiting

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

NCT06366789AML With Gene Mutations

Lomond Therapeutics Holdings, Inc.

Phase 1

150

2024-05-29

Recruiting

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

NCT05266846ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy

DrugsPemetrexed·Bevacizumab·Cisplatin·Pembrolizumab

Hunan Province Tumor Hospital

Phase 2

Changsha

2024-05-29

Active, closed

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

DrugsAnvumetostat·Modified FOLFIRINOX·Cetuximab·Nab-paclitaxel

Amgen

Phase 1

120

Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun

2024-05-29

Recruiting

A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT06405425Urothelial Carcinoma

DrugIza-bren

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2

Shanghai

2024-05-29

Recruiting

Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival

NCT06256354Cancer Surgery, Intraoperative Hypothermia, Targeted Temperature Management, Postoperative Delirium

Peking University First Hospital

Not applicable

3,992

Chizhou, Hefei, Ma’anshan, Beijing, Chongqing, Shenzhen, Shijiazhuang, Harbin

2024-05-29

Active, closed

A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT06470438Lymphoma, Non-Hodgkin, Refractory B-Cell NHL, Relapsed B-cell NHL

Janssen Research & Development, LLC

Phase 1

Beijing, Guangzhou, Hangzhou, Shanghai, Tianjin

2024-05-28

Recruiting

AI-Enhanced Optimization of Acute Levodopa Challenge Test

NCT06949865Vascular Parkinsonism, Drug-induced Parkinsonism, Corticobasal Degeneration (CBD), Parkinson Disease (PD)

Beijing Tiantan Hospital

Observational

2,000

Beijing

2024-05-28

Recruiting

A Clinical Study of SPH7854 Granules in Healthy Subjects.

NCT06483373Inflammatory Bowel Disease

Shanghai Pharmaceuticals Holding Co., Ltd

Early Phase 1

111

Chengdu

2024-05-28

Recruiting

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT06417008Non-Squamous Non-Small Cell Lung Cancer

DrugsHS-20117·Almonertinib

Hansoh BioMedical R&D Company

Phase 2/3

1,080

Tianjin, Hangzhou

2024-05-28

Recruiting

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

NCT06489808Relapsed/Refractory Large B-Cell Lymphoma

DrugsLinperlisib·Mitoxantrone Hydrochloride Liposome·Ifosfamide·Vinorelbine

Institute of Hematology & Blood Diseases Hospital, China

Phase 2

Tianjin

2024-05-28

Recruiting

Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST

NCT06507683Gastrointestinal Stromal Tumors

First Affiliated Hospital of Chongqing Medical University

Not applicable

Chongqing

2024-05-28

Recruiting

PET Imaging of 68Ga-Her2-affibody in Tumors with High Her2 Expression

NCT06289517Neoplasms

Peking University First Hospital

Not applicable

Beijing

2024-05-28

Recruiting

Intratumoral CAN2109 in Subjects With Solid Tumors

NCT06332430Solid Tumor, Lymphoma

Canwell Biotech Limited

Phase 1

Guangzhou

2024-05-28

Recruiting

Sulfamethoxazole Prophylaxis Duration After Renal Transplantation

NCT07231770Fever, Chest Tightness

Anhui Provincial Hospital

Not applicable

450

Hefei

2024-05-28

Recruiting

The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation

NCT07314047Brain Arteriovenous Malformation, Arteriovenous Fistula

MicroPort NeuroTech Co., Ltd.

Not applicable

116

Shanghai

2024-05-28

By invitation

A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma

NCT06424626Melanoma, Mucosal Melanoma, Metastatic Melanoma

DrugsAxitinib·Cadonilimab·Ivonescimab

Peking University Cancer Hospital & Institute

Phase 1

Beijing

2024-05-28

Recruiting

Expressions of Ezrin and Pip5k1α Proteins in Airway Smooth Muscle of Asthmatic Patients

NCT06427018Asthma, Protein

Lei-Miao Yin

Observational

120

Shanghai

2024-05-28

Recruiting

Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial

NCT06329635Aneurysmal Subarachnoid Hemorrhage, Vasospasm

DrugNicardipine

The Affiliated Hospital Of Guizhou Medical University

Not applicable

396

Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanning, Guiyang, Kaili

2024-05-27

Active, closed

A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma

NCT06464185B-cell Non-Hodgkin Lymphoma

Institute of Hematology & Blood Diseases Hospital, China

Phase 1/2

Tianjin

2024-05-27

Recruiting

CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction

NCT06389305B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia

Beijing GoBroad Hospital

Not applicable

213

Beijing

2024-05-27

Recruiting

A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

NCT06387082Hematological Malignancies

Hutchmed

Phase 1

132

Changsha, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Jinan

2024-05-27

Recruiting

A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

NCT06417554Advanced Solid Tumors

DrugsSHR-A2102·Disitamab Vedotin·Adebrelimab

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 1/2

Beijing

2024-05-27

Not yet open

The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases

NCT06420154Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy

First Affiliated Hospital of Wenzhou Medical University

Early Phase 1

Wenzhou

2024-05-27

Recruiting

A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia

NCT06302491β -Thalassemia

DrugAND017

Kind Pharmaceuticals LLC

Phase 2

Guangzhou, Maoming, Liuzhou, Nanning, Haikou

2024-05-27

Recruiting

Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT

NCT06423131Graft-Versus-Host Disease, Hematopoietic Stem Cell Transplantation, Child, Only, Haploidentical Hematopoietic Stem Cell Transplantation

Sijia Gu

Not applicable

110

Shanghai

2024-05-26

Recruiting

Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

NCT06437353Ovarian Cancer

DrugsSurufatinib·Paclitaxel·Carboplatin

Anhui Provincial Cancer Hospital

Phase 2

Hefei

2024-05-25

Recruiting

Linperlisib Combined With Chidamide in Patients With PTCL

NCT06421948Peripheral T-cell Lymphoma

Yanyan Liu

Phase 1/2

134

Zhengzhou, Wuhan, Changsha, Chengdu, Tianjin, Hangzhou

2024-05-25

Recruiting

Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

NCT06441565Colorectal Cancer

DrugsFruquintinib·Fluorouracil·Adrucil·Oxaliplatin

Sun Yat-sen University

Phase 2/3

Guangzhou

2024-05-24

Recruiting

A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma

NCT06341556Mantle Cell Lymphoma, Maintenance Therapy

DrugZanubrutinib

Fudan University

Phase 2

Shanghai

2024-05-24

Recruiting

Impact of External Drainage of the Main Pancreatic Duct and Common Bile Duct on Pancreatic Fistula Following Pancreaticoduodenectomy

NCT06322680Pancreaticoduodenectomy

Shanghai Zhongshan Hospital

Not applicable

322

Shanghai

2024-05-24

Recruiting

Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis

NCT06436534Rhinitis, Allergic

DrugGanciclovir

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Not applicable

Wuhan

2024-05-24

Recruiting

Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)

NCT06458010Familial Hypercholesterolemia

RenJi Hospital

Early Phase 1

Shanghai

2024-05-24

Recruiting

Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials

NCT06612632Cancer

DrugToripalimab

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2

100

Beijing

2024-05-24

Recruiting

Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.

NCT06659653Acute Lymphoblastic Leukemia

Tan Jie

Early Phase 1

Jinzhou

2024-05-24

Active, closed

Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC

NCT06490107Biliary Tract Cancer

DrugsTeysuno·Durvalumab

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2024-05-24

Recruiting

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

NCT06345729Non-small Cell Lung Cancer

DrugsCalderasib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

348

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Jiamusi

2024-05-24

Recruiting

MRD Response-adapted Allo-HSCT for Adverse-risk AML

NCT06301425Acute Myeloid Leukemia

Peking University People's Hospital

Not applicable

178

Beijing

2024-05-24

Recruiting

A Study of GLB-001 in Patients With Myeloid Malignancies

NCT06378437Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes

DrugGLB-001

Hangzhou GluBio Pharmaceutical Co., Ltd.

Phase 1

108

Hefei, Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang

2024-05-24

Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

NCT06375044Relapsed or Refractory Multiple Myeloma

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1

130

Beijing, Fuzhou, Guangzhou, Zhengzhou, Nanjing, Tianjin, Hanzhou

2024-05-24

Recruiting

A Study of GQ1010 in Subjects With Advanced Solid Tumors

NCT06464055Advanced Malignant Solid Tumors

DrugPhase II

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Phase 1/2

260

Beijing, Harbin, Tianjin, Wuhan, Zhengzhou

2024-05-23

Recruiting

Clinical Effects of Keratinized Mucosa Augmentation Around Dental Implant With Free Gingival Graft in Different Surgical Timing at Mandibular Posterior Sites

NCT07088172Edentulous Alveolar Ridge In Mandible

The Dental Hospital of Zhejiang University School of Medicine

Not applicable

Hangzhou

2024-05-23

Recruiting

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients

NCT06569485DLBCL

DrugsTrilaciclib·R-Chop

Sun Yat-sen University

Phase 2

Guangzhou

2024-05-23

Recruiting

Spectral CT in Radiotherapy for Cervical Cancer

NCT06433817Cervical Cancer, Radiotherapy

Peking Union Medical College Hospital

Observational

150

Beijing

2024-05-22

Recruiting

Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study

NCT06482788Esophagogastric Junction Adenocarcinoma

DrugsXelox·Adebrelimab

Ruijin Hospital

Phase 2

Shanghai

2024-05-22

Active, closed

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)

NCT06382116Non-small Cell Lung Cancer

DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3

432

Guangzhou

2024-05-22

Recruiting

Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases

NCT06542159Adaptive Radiotherapy, Stereotactic Body Radiotherapy, Non-small Cell Lung Cancer, Lung Oligometastases

Sun Yat-sen University

Phase 2

130

Guangzhou

2024-05-22

Recruiting

Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)

NCT06911606SCLC, Limited Stage

DrugsEtoposide and carboplatin·Cisplatin

Guangdong Provincial People's Hospital

Phase 2

Guangzhou

2024-05-22

Active, closed

Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy

NCT06414577Nasopharyngeal Cancer

DrugIrinotecan Liposomal

XIANG YANQUN

Phase 2

Guangzhou

2024-05-22

Recruiting

A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients

NCT06344091Local Analgesia Via Infiltration

DrugBupivacaine Liposome

Jiangsu HengRui Medicine Co., Ltd.

Phase 4

232

Guangzhou

2024-05-21

Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210Small Cell Lung Cancer

DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan

Daiichi Sankyo

Phase 3

540

Beijing, Changchun, Changsha, Chengdu, Chongqing, Haerbin, Hangzhou, Jiangxi

2024-05-21

Recruiting

Intra- and Interindividual Moderators of Prefrontal Excitability Investigated Using Simultaneous TMS With Neuroimaging

NCT06976879Healthy Adults

The Hong Kong Polytechnic University

Observational

Hong Kong

2024-05-21

Recruiting

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

NCT06133972Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

550

Guangzhou, Shantou, Nanjing, Suzhou, Nanchang, Pingxiang, Changchun, Linyi

2024-05-21

Recruiting

Clinical Study of HIFU for Localized Prostate Cancer

NCT06362577Localized Prostate Cancer

RenJi Hospital

Observational

Shanghai

2024-05-21

Recruiting

Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia

NCT06607419B-Cell Lymphoblastic Leukemia

DrugBlinatumomab

Shanghai Jiao Tong University School of Medicine

Phase 2/3

Hefei, Fuzhou, Shanghai, Ningbo

2024-05-21

Recruiting

ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection

NCT07573943Chronic Hepatitis b

DrugsPeg-IFNα·Entecavir

The Second Affiliated Hospital of Chongqing Medical University

Phase 4

120

Chongqing

2024-05-21

Recruiting

Acupuncture of Different Treatment Frequency in Chronic Plantar Fasciitis

NCT06284993Plantar Fasciitis, Chronic

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Not applicable

Beijing

2024-05-21

Recruiting

County Medical Community-based, Cardiovascular Risk Stratified Integrated Care Model: a Pragmatic Cluster Randomised Control Trial

NCT06302127Hypertension, Diabetes Mellitus Type 2, Cardiovascular Diseases

Peking University

Not applicable

2,560

Sanming, Liuzhou

2024-05-20

Active, closed

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386Prostatic Neoplasms, Castration-Resistant

DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Taxotere

Merck Sharp & Dohme LLC

Phase 1/2

220

2024-05-20

Recruiting

Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris

NCT06403501Acne Vulgaris

Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

Phase 3

692

Shanghai

2024-05-20

Recruiting

Artificial Intelligence-assisted System in Colonoscopy

NCT06406062Adenoma Colon Polyp

Renmin Hospital of Wuhan University

Observational

7,500

Wuhan

2024-05-20

Recruiting

Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma

NCT06824883Extranodal NK/T-cell Lymphoma

Peking Union Medical College Hospital

Phase 2

Beijing

2024-05-20

By invitation

A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus

NCT06925334Type 2 Diabetic Patients

DrugDegludec insulin

Beijing Tsinghua Chang Gung Hospital

Phase 4

170

Beijing

2024-05-20

Recruiting

Predictive Effect of TGF-β and INS-PI3K-AKT Related Proteins for POD in Diabetes Patients

NCT06426953Diabetes, Postoperative Delirium

Xie Kangjie

Observational

180

Duyun, Hangzhou

2024-05-20

Recruiting

68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease

NCT06387381PSMA, FAP, Positron-Emission Tomography

First Affiliated Hospital of Chongqing Medical University

Early Phase 1

Chongqing

2024-05-20

Recruiting

Pelvic Floor Rehabilitation of Female Pelvic Floor Dysfunction

NCT06461234Pelvic Floor Disorders, Pelvic Organ Prolapse

Mingfu Wu

Observational

1,360

Wuhan

2024-05-20

Recruiting

IDEAL Study: Blinded RCT for the Impact of AI Model for Cerebral Aneurysms Detection on Patients' Diagnosis and Outcomes

NCT06118840Intracranial Aneurysm, CT Angiography, Deep Learning, Double Bind Interaction

Jinling Hospital, China

Not applicable

6,450

Hefei, Wuhu, Guiyang, Zhengzhou, Shiyan, Nanjing, Xuzhou, Changchun

2024-05-20

Not yet open

Evaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer

NCT06421220Gastric Cancer

Qilu Hospital of Shandong University

Not applicable

484

Jinan

2024-05-20

Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection

Vedanta Biosciences, Inc.

Phase 3

852

2024-05-20

Recruiting

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

NCT06307665Asthma

AstraZeneca

Phase 3

440

Beijing, Bengbu, Chengdu, Chongqing, Hohhot, Mianyang, Shanghai, Shantou

2024-05-20

Recruiting

99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer

NCT06419348Prostate Cancer Stage, PSMA, SPECT

First Affiliated Hospital of Chongqing Medical University

Early Phase 1

Chongqing

2024-05-20

By invitation

A Randomized Controlled Trial of the "Psychological Training Camp & Obstetrician-Led Psychoprenatal Intervention (PICONI)" Stepwise Intervention Model for Depression and Anxiety During Pregnancy.

NCT06383221Perinatal Depression, Stepped Care, Perinatal Anxiety

Fangbiao Tao

Not applicable

600

Ma’anshan

2024-05-20

Recruiting

Sources and Mechanisms of Energy Compensation

NCT06432517Energy Expenditure, Exercise, Energy Intake, Food Preferences

Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences

Not applicable

Shenzhen

2024-05-20

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang

2024-05-19

Active, closed

A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06328439Locally Advanced or Metastatic Solid Tumors

DrugANS014004

Avistone Biotechnology Co., Ltd.

Phase 1

Shanghai

2024-05-19

Recruiting

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

NCT06424899Non Small Cell Lung Cancer

DrugAdebrelimab

Zeng Jian

Phase 2

Hangzhou

2024-05-19

Recruiting

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

NCT06415669Gastric/Gastroesophageal Junction Adenocarcinoma

DrugsApatinib Mesylate·Adebrelimab·Paclitaxel

The First Affiliated Hospital of Xiamen University

Phase 2

Fuzhou

2024-05-19

Recruiting

Screening of Biomarkers and Related Mechanisms for RIX

NCT07170358Xerostomia Due to Radiotherapy (Disorder)

Second Affiliated Hospital, Zhejiang University, School of Medicine

Observational

Nanjing, Hangzhou

2024-05-17

Recruiting

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

NCT06421298Lung Cancer

DrugsTafolecimab·Sintilimab·Nab-paclitaxel·Docetaxel

Jinghui Wang

Phase 2

Beijing

2024-05-17

By invitation

Protocol for Evaluating Physiological and Psychological Adaptation Mechanisms in Tibetan Plateau Environments

NCT06557928High Altitude

Peking Union Medical College Hospital

Observational

Beijing

2024-05-17

Recruiting

Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma

NCT06516133Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3

494

Guangzhou

2024-05-17

Active, closed

A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)

NCT06382129Non-small Cell Lung Cancer

DrugsIza-bren·Docetaxel

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3

698

Beijing

2024-05-17

Active, closed

The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

NCT06357806Chronic Hepatitis B

DrugsETV/TDF/TAF·PEG IFNα-2b·Sintilimab

Beijing 302 Hospital

Not applicable

Beijing

2024-05-17

Active, closed

Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC

NCT06477523SCLC, Extensive Stage

DrugsCadonilimab·Etoposide·Carboplatin

Sichuan University

Phase 1/2

Chengdu

2024-05-16

Recruiting

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

NCT06420973Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma

DrugDisitamab Vedotin

Peking University Cancer Hospital & Institute

Phase 2

Beijing

2024-05-16

Recruiting

GDFT on the Postoperative Outcome in Head and Neck Cancer Surgery

NCT06468852Postoperative Complications

Beijing Tongren Hospital

Not applicable

340

Beijing

2024-05-16

Recruiting

Fluorouracil Treatment Via Colon for Colorectal Cancer

NCT06385418Colorectal Cancer

The Second Hospital of Nanjing Medical University

Phase 2

Nanjing

2024-05-16

Recruiting

Genetic Markers of Diabetic Ulcers and Personalized Treatment Targets Research

NCT06979037Diabetic Ulcers

The First Affiliated Hospital of University of South China

Observational

712

Hengyang

2024-05-16

Recruiting

Thalidomide Therapy for VEOIBD

NCT06382519Inflammatory Bowel Diseases

DrugThalidomide

Children's Hospital of Fudan University

Observational

Shanghai

2024-05-15

Recruiting

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

NCT06378138Hematologic Malignancies

DrugsICP-248·Orelabrutinib

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 2/3

226

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou

2024-05-15

Recruiting

The Safety and Effectiveness of NEPA in Preventing Postoperative Nausea and Vomiting After General Anesthesia Gastrointestinal Cancer Surgery: A Single-Center Retrospective Study

NCT06417567General Anesthesia Gastrointestinal Cancer Surgery

DrugNEPA

Tianjin Medical University Cancer Institute and Hospital

Observational

Tianjin

2024-05-15

Not yet open

A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)

NCT06340490Systemic Lupus Erythematosus

DrugsFludarabine·Cyclophosphamide

Guangdong Ruishun Biotech Co., Ltd

Phase 1

Beijing, Nanjing, Shanghai

2024-05-15

Recruiting

Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection

NCT06541327Lymphoma, Non-Hodgkin

Ruijin Hospital

Observational

1,000

Shanghai

2024-05-15

Active, closed

A Comparative Study of Neoadjuvant Chemotherapy Versus Upfront Radical Surgery for Upper Tract Urothelial Carcinoma

NCT07155044UTUC, UC (Urothelial Cancer)

Changhai Hospital

Observational

120

Shanghai

2024-05-15

Recruiting

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

NCT06383780Nasopharyngeal Carcinoma

DrugTislelizumab

XIANG YANQUN

Phase 3

Guangzhou

2024-05-15

Recruiting

Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy

NCT06382103Hepatocellular Carcinoma

Shanghai Zhongshan Hospital

Observational

240

Shanghai

2024-05-15

Recruiting

Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

NCT06406634Hepatocellular Carcinoma

DrugsCadonilimab·Lenvatinib

Hunan Cancer Hospital

Phase 2

Changsha

2024-05-15

Recruiting

A Study of JMT203 in Patients With Cancer Cachexia

NCT06868849Non Small Cell Lung Cancer, Pancreatic Cancer, Cancer Cachexia, Colorectal Cancer Cachexia

Shanghai JMT-Bio Inc.

Phase 1/2

307

Zhejiang

2024-05-15

Active, closed

A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

NCT06396039Relapsing Multiple Sclerosis

DrugOzanimod

Bristol-Myers Squibb

Phase 4

Beijing, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanchang

2024-05-15

Active, closed

Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer

NCT06429904Locally Advanced Pancreatic Cancer

DrugsNalirifox·Nimotuzumab

Peking Union Medical College Hospital

Phase 2

Beijing

2024-05-15

Recruiting

Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

NCT06364956Bladder Cancer

DrugTislelizumab

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1/2

Guangzhou, Wuhan, Changsha

2024-05-15

Recruiting

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

NCT06250972Pancreatic Adenocarcinoma

Fudan University

Phase 3

210

Shanghai

2024-05-15

Recruiting

Clinical Outcome in Patients With INPH

NCT06428734Hydrocephalus, Idiopathic Normal Pressure Hydrocephalus, CSF, Glympathic System

Xuanwu Hospital, Beijing

Observational

200

Beijing

2024-05-15

Recruiting

Prebiotics and the Management of Hyperuricemia

NCT06420401Subjects With Hyperuricemia

Sun Yat-sen University

Not applicable

160

Guangzhou

2024-05-15

Recruiting

A Study of MT027 in Patients with Pleural Malignant Tumors

NCT06726564Advanced Malignant Solid Tumor, Malignant Pleural Effusion, Pleura Carcinoma, Pleural Mesothelioma

DrugMT027 cells

Suzhou Maximum Bio-tech Co., Ltd.

Phase 1

Beijing

2024-05-15

Recruiting

Identification for High Risk of Coronary Heart Disease Based on Quantitative Analysis of Fundus Vessels and Metabolic Molecules

NCT07773064Coronary Artery Disease

Beijing Hospital

Observational

3,000

Beijing

2024-05-14

Active, closed

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

NCT06079359Hypophosphatasia

DrugALXN1850

Alexion Pharmaceuticals, Inc.

Phase 3

Beijing, Guangzhou, Shanghai, Shenzhen

2024-05-14

Recruiting

Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)

NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)

DrugsKeytruda·Pembrolizumab

Inhibrx Biosciences, Inc

Phase 2/3

450

2024-05-14

Recruiting

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

NCT07234162Peripheral T-cell Lymphoma

DrugsGolidocitinib·Chidamide·Gemcitabine

Dizal Pharmaceuticals

Phase 3

218

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning

2024-05-13

By invitation

Electroencephalogram Characteristics of Surgical Anesthetized Patients and Postoperative Dilirium

NCT06394778Electroencephalogram, Postoperative Delirium (POD)

First Affiliated Hospital of Zhejiang University

Observational

375

Hangzhou

2024-05-13

Recruiting

Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)

NCT06427460Pancreatic Cancer

Changhai Hospital

Phase 2

Shanghai

2024-05-12

Recruiting

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

NCT06190275HNSCC

DrugsGT201·Venetocalx

Grit Biotechnology

Not applicable

Shanghai

2024-05-12

Recruiting

MRD-positive AML Clinical Study

NCT07131059AML, Adult

DrugsAvapritinib·Mitoxantrone·Idarubicin·Gilteritinib

Institute of Hematology & Blood Diseases Hospital, China

Not applicable

537

Tianjin

2024-05-11

Recruiting

Study on the Mechanism of Yifei Moxibustion Improving Immune Function in COPD Based on Plasma Exosome miRNAs

NCT07131020Stable COPD Patients

Henan University of Traditional Chinese Medicine

Not applicable

120

Zhengzhou

2024-05-11

Active, closed

An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia

NCT06308159Beta-Thalassemia

Lantu Biopharma

Phase 1/2

Kunming

2024-05-11

Recruiting

Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients

NCT05990556Glioblastoma, Meningeal Arteries

First Affiliated Hospital, Sun Yat-Sen University

Not applicable

Guangzhou

2024-05-11

Recruiting

GPC3/Mesothelin-CAR-γδT Cells Against Cancers

NCT06196294Pancreas Cancer, Lung Cancer, Liver Cancer, Mesothelioma

Second Affiliated Hospital of Guangzhou Medical University

Phase 1

Guangzhou

2024-05-10

By invitation

Effects of Unilateral, Bilateral and Combined Resistance Training on the Speed and Accuracy of the Serve in Youth Tennis Players

NCT06419452Exercise Training

Universiti Putra Malaysia

Not applicable

Lanzhou

2024-05-10

Recruiting

Probiotics Combined with Enteral Nutrition Reduces Postoperative Infectious Complications in PD

NCT06719596Infectious Complications

DrugBifidobacterium Bifidum

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 1/2

Nanjing

2024-05-10

Recruiting

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients

NCT06421831Spinal Muscular Atrophy Type 3

GeneCradle Inc

Phase 1/2

Beijing

2024-05-10

Recruiting

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

NCT06394492Ovarian Cancer

DrugsSHR-A1921·Topotecan·Doxorubicin·Paclitaxel

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

440

Beijing, Hangzhou

2024-05-10

Recruiting

Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)

NCT05738616Advanced Hepatocellular Carcinoma

Wen Tianfu

Phase 3

196

Chengdu

2024-05-10

By invitation

Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia

NCT06711679Pediatric ALL

DrugRopivacaine

Yilin Zhao

Phase 4

180

Wuhan

2024-05-10

Not yet open

Multiple Study of Electroaccpuncture in ARDS

NCT06278675Acute Respiratory Distress Syndrome, Sepsis

Nanjing University of Traditional Chinese Medicine

Not applicable

264

Nanjing

2024-05-10

Recruiting

Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer

NCT06411678Breast Cancer

Drug68GA-DOTA-dPNE

Peking Union Medical College Hospital

Early Phase 1

Dongcheng

2024-05-10

Recruiting

Treatment of Primary Coronary Artery Vascular Lesions With Biolimus Coated Coronary Balloon Dilation Catheter

NCT06385067Coronary Artery Disease

JW Medical Systems Ltd

Observational

400

Lanzhou, Nanning

2024-05-10

Recruiting

[18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease

NCT06833645Alzheimer's Disease

Sichuan Provincial People's Hospital

Observational

280

Chengdu

2024-05-10

Recruiting

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

NCT06413992Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic

DrugsFluzoparib·Camrelizumab·Paclitaxel·Carboplatin

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

117

Beijing

2024-05-10

Recruiting

Risk Stratification and New Early Prevention and Treatment Strategies for Patients With Cardiomyopathy (STRENGTH）

NCT06352320Cardiomyopathies

First Affiliated Hospital Xi'an Jiaotong University

Observational

500

Xi'an

2024-05-09

Recruiting

Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR）

NCT05965362Infective Endocarditis

First Affiliated Hospital Xi'an Jiaotong University

Observational

2,000

Xi'an

2024-05-09

By invitation

18F-FES PET/CT in the Treatment Planning, and Response Assessment of ER-Positive Breast Cancer

NCT07859046Breast Cancer

Hunan Cancer Hospital

Observational

100

Changsha

2024-05-09

Active, closed

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

NCT06439576Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Observational

1,000

Shantou, Luoyang, Shiyan, Xuzhou, Fushun, Panjin, Shenyang, Weifang

2024-05-09

Recruiting

A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

NCT06298058Advanced Solid Tumor

Shanghai Institute Of Biological Products

Phase 1

144

Shanghai

2024-05-09

Recruiting

A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma

NCT06436677Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T Cell Lymphoma

Peking University First Hospital

Observational

100

Beijing

2024-05-09

Recruiting

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT06395870B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory

Tianjin Medical University Cancer Institute and Hospital

Phase 1

Hefei, Tianjin

2024-05-09

Active, closed

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

NCT06316531HER2-positive Breast Cancer

DrugsT-Bren·Trastuzumab emtansine

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3

274

Guangzhou

2024-05-08

Recruiting

Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer

NCT06487429Gastric Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2

Wuhan

2024-05-08

Recruiting

Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors

NCT06195384Solid Tumor, Adult

Second Affiliated Hospital of Guangzhou Medical University

Phase 1

Guangzhou

2024-05-08

Active, closed

A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors

NCT06376136Advanced Solid Tumors

Bio-Thera Solutions

Phase 1/2

218

Guangzhou

2024-05-08

Recruiting

Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS

NCT05795140Atypical Hemolytic Uremic Syndrome

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

Beijing

2024-05-08

Active, closed

A Clinical Trial Comparing Staged Turnbull-Cutait Pull-through Anastomosis With Direct Anastomosis Plus Prophylactic Ileostomy in the Treatment of Low Rectal Cancer After Internal Sphincter Resection

NCT06662643Rectal Cancer, Rectal Carcinoma

Zhongnan Hospital

Not applicable

110

Wuhan

2024-05-08

Recruiting

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

NCT06289062Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation

DrugsCamrelizumab·Nab-paclitaxel·Cisplatin

Tongji Hospital

Phase 2

Guangzhou, Wuhan

2024-05-08

Recruiting

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

NCT06455124Rectal Cancer

DrugsXeloda·Toripalimab·Capecitabine·Oxaliplatin

Fudan University

Phase 2

Shanghai

2024-05-08

Recruiting

A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors

NCT06431243Advanced Solid Tumor

Chengdu Zenitar Biomedical Technology Co., Ltd

Phase 1/2

132

Guanzhou, Chengdu

2024-05-08

Active, closed

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 3

1,541

Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan

2024-05-08

Recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

NCT06361888Metastatic Pancreatic Cancer

DrugsSurufatinib·Nab-paclitaxel·Gemcitabine

Hutchmed

Phase 2/3

502

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Nanning, Guandong

2024-05-08

Recruiting

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

NCT06446128Non-Hodgkin Lymphoma, B-cell

Shanghai Cell Therapy Group Co.,Ltd

Early Phase 1

Shanghai

2024-05-07

Recruiting

The Impact and Effect of Traditional Chinese Medicine Treatment on Organ Failure in Critically Ill Patients

NCT06452966Organ Failure, Multiple, Indigestion, Delayed Gastric Emptying, Respiratory Failure

China Medical University Hospital

Not applicable

350

2024-05-07

Recruiting

AMT-116 in Patients with Solid Tumors

NCT06782334Advanced Solid Tumors

DrugAMT-116

Multitude Therapeutics Inc.

Phase 1/2

144

Fuzhou, Dongguan, Guangzhou, Nanning, Changsha, Hangzhou, Wenzhou

2024-05-07

Recruiting

Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours

NCT06430502Cancer, PD-L1 Gene Mutation

Wuxi People's Hospital

Not applicable

200

Wuxi

2024-05-07

By invitation

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

NCT06215846Solid Tumor

DrugBioTTT001

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Phase 1

Shenyang

2024-05-07

Recruiting

A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

NCT06300320Chronic Graft Versus Host Disease

DrugRovadicitinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

Hefei, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Xiangyang, Taian, Shanghai

2024-05-07

Not yet open

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer

NCT06404736Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer

DrugsAlbumin-Bound Paclitaxel·Carboplatin

Fudan University

Phase 2

Shanghai

2024-05-07

Recruiting

PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY

NCT06354140Esophageal Squamous Cell Carcinoma

DrugsTegafur·Tislelizumab

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 2

Chongqing

2024-05-07

Recruiting

Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT06521255DLBCL

DrugsTafasitamab·Lenalidomide·Rituximab·Oxaliplatin

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 3

244

Beijing, Changchun, Changsha, Chaozhou, Chengdu, Chongqing, Guangzhou, Hangzhou

2024-05-07

Recruiting

Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer

NCT06478225Tumor Pancreas

RenJi Hospital

Not applicable

Shanghai

2024-05-07

Not yet open

Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer

NCT06255379Metastasis Colorectal Cancer, Colon Cancer, Rectal Cancer

DrugsFuquinitinib·Tegafur Gimeracil Oteracil

Guangzhou University of Traditional Chinese Medicine

Phase 2

Guangzhou

2024-05-06

Active, closed

A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis

NCT06457425MF,PMF,PPV-MF,PET-MF

DrugsFlonoltinib·Ruxolitinib

Chengdu Zenitar Biomedical Technology Co., Ltd

Phase 2

Chengdu, Tianjin

2024-05-06

Recruiting

The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer

NCT06368063Pancreatic Cancer Resectable

DrugHuaier

Xi'an Jiaotong University

Phase 4

642

Xi'an

2024-05-06

Recruiting

Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

NCT06342466Systemic Amyloidosis

DrugsVelcade·Pomalidomide·Bortezomib·Dexamethasone

Jin Lu, MD

Phase 2

Beijing

2024-05-06

Not yet open

A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites

NCT06415500Gynecologic Cancer

DrugNkr-Nk

Anhui Provincial Hospital

Phase 1

Hefei

2024-05-06

Recruiting

Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection

NCT06406816Intrahepatic Cholangiocarcinoma

Yongyi Zeng

Early Phase 1

Fuzhou

2024-05-06

Recruiting

Efficacy of TEAS on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy

NCT06341270Liver Cancer

West China Hospital

Not applicable

524

Chengdu

2024-05-06

Not yet open

A Correlation Study of Cognitive Function in Patients With Depression

NCT05396989Depression

Central South University

Observational

200

Changsha

2024-05-06

Recruiting

A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE

NCT06380309Advanced Malignant Solid Tumor of Digestive System

Peking University

Early Phase 1

Beijing

2024-05-06

Recruiting

The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor

NCT06311968Thymus Epithelial Tumor, Proton Radiotherapy, Radiation Toxicity

Jian Chen

Phase 2

Shanghai

2024-05-06

Recruiting

Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

NCT06574698Neuroblastoma, GD2 Antibody (Naxitamab)

Guangzhou Women and Children's Medical Center

Observational

Guanzhou

2024-05-06

Active, closed

HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction

NCT06391710Heart Failure With Preserved Ejection Fraction

DrugHRS9531

Fujian Shengdi Pharmaceutical Co., Ltd.

Phase 2

203

Beijing

2024-05-06

Recruiting

A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors

NCT06717022Mesothelin Positive Tumors

Tianjin Medical University Cancer Institute and Hospital

Not applicable

Tianjin

2024-05-06

By invitation

Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation

NCT06405295Breast Carcinoma, BRCA Mutation, Adjuvant Drug Therapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Observational

600

Beijing

2024-05-06

By invitation

Effect of (neo)Adjuvant Therapy on Lipids in Young Breast Cancer Patients

NCT06405269Breast Neoplasms, Lipid Profile

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Observational

600

Beijing

2024-05-06

By invitation

A Prospective, Randomized, Open, Parallel-controlled, Superior-efficacy Clinical Study of Radical Sigmoidectomy for Sigmoid Cancer Versus Radical Sigmoidectomy Combined with Indocyanine Green Fluorescence Imaging Lymphatic Tracing Dissection in the Treatment of Sigmoid Cancer

NCT06396806Sigmoid Cancer

Sun Yat-sen University

Not applicable

1,072

Guangzhou

2024-05-06

By invitation

Unique Electroencephalography (EEG) Markers of Habit Behaviors in Obsessive-Compulsive Disorder (OCD)

NCT06882902Obsessive-Compulsive Disorder

Shanghai Mental Health Center

Not applicable

Shanghai

2024-05-05

Recruiting

Peripheral-central Correlation Study on the Treatment of Chronic Tinnitus With "Dao qi Tong Luo" Based on the Theory of "Connecting the Two Ears to the Brain"

NCT06401993Tinnitus

The Third Affiliated hospital of Zhejiang Chinese Medical University

Not applicable

Hangzhou

2024-05-04

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

473

Hefei, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Shijiazhuang

2024-05-03

Recruiting

Dalpiciclib in HR+/HER2- ABC

NCT06301438Advanced Breast Cancer

DrugDalpiciclib

RenJi Hospital

Observational

103

Shanghai

2024-05-03

Recruiting

Comparison of MRI Artificial Intelligence-guided cTB Versus Routine cTB in Prostate Cancer Diagnosis

NCT06392737Prostate Cancer

Peking University First Hospital

Not applicable

360

Beijing

2024-05-01

Recruiting

Research on Body Voice AI Recognition System for Children's Health Management

NCT06542120Congenital Heart Disease, Bronchopneumonia, Abdominal Disease

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Observational

30,000

Wuhan, Changsha, Shanghai, Kunming

2024-05-01

Recruiting

Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm

NCT06634979Lung Cancer (NSCLC), Lymph Node Dissection

Fudan University

Not applicable

684

Shanghai

2024-05-01

Recruiting

Characteristics of Papez Loop Neural Network in T2DM （Type 2 Diabetes Mellitus）

NCT06912321Type 2 Diabetes, Insulin Resistance, Cognitive Impairment

Nanjing First Hospital, Nanjing Medical University

Observational

400

Nanjing

2024-05-01

Recruiting

Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer

NCT06421376Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy

DrugCardonilizumab

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Anyang, Xinxiang, Beijing

2024-05-01

Recruiting

Correlation Between PLA Levels and Disease Severity in Patients With Sepsis Cardiac Insufficiency

NCT06655389Sepsis Cardiac Insufficiency

Dongzhimen Hospital, Beijing

Observational

Beijing

2024-05-01

Not yet open

Washed Microbiota Transplantation for Rhinitis

NCT06350448Rhinitis

DrugWashed Microbiota Transplantation

The Second Hospital of Nanjing Medical University

Not applicable

Nanjing

2024-05-01

Recruiting

The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT

NCT06362967High Titers of Anti-HLA Antibody (MFI ≥5000)

Anhui Provincial Hospital

Phase 2

Hefei

2024-05-01

Recruiting

A Multimodal Prospective Cohort Study of Parkinsonism

NCT07553845Parkinsonism, REM Sleep Behavior Disorder

Ruijin Hospital

Observational

640

Shanghai

2024-05-01

Recruiting

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

NCT06440954Non-Small Cell Lung Cancer

DrugPemetrexed

Hunan Province Tumor Hospital

Phase 2

220

Changsha

2024-05-01

Active, closed

A Multi-center Clinical Study of Zanubrutinib in Combination With First-line Chemoimmunotherapy in Patients With Grade 3A High-risk Follicular Lymphoma

NCT06742879Follicular Lymphoma

Zhengzhou University

Observational

Zhengzhou

2024-05-01

Recruiting

BAI-BACE for Advanced Lung Squamous Cell Carcinoma

NCT06377735Squamous Cell Carcinoma

Sun Yat-sen University

Not applicable

Beijing

2024-05-01

Recruiting

De-Escalation Postoperative Radiotherapy for Oral Squamous Cell Carcinoma With pCR/MPR.

NCT06353685De-escalated Radiotherapy; Head and Neck Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

103

Guangzhou

2024-05-01

Recruiting

Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients

NCT065616203-year Disease-free Survival

DrugBefotertinib

Fudan University

Phase 4

592

Shanghai

2024-05-01

Not yet open

REspiratory diSEAse cohoRt Studies of CHinese Medicine for Asthma (RESEARCH- Asthma)

NCT06373692Bronchial Asthma

Henan University of Traditional Chinese Medicine

Observational

1,508

Zhengzhou

2024-05-01

Not yet open

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

NCT06324994Mantle Cell Lymphoma

DrugLinperlisib

Dalian Medical University

Phase 2

Dalian

2024-05-01

Recruiting

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

NCT07282262Biliary Tract Cancer

DrugsIvosidenib·Lenvatinib

Peking Union Medical College Hospital

Phase 2

300

Beijing

2024-05-01

Active, closed

Clinical Study on the Impact of Eradication of Oral Porphyromonas Gingivalis on the Prognosis of Early Esophageal Cancer After ESD Surgery

NCT06722300Esophageal Cancer

The First Affiliated Hospital of Henan University of Science and Technology

Not applicable

856

Luoyang

2024-05-01

Active, closed

Hemodialysis-Induced Renal Perfusion Decline: Unraveling the Pathophysiological Mechanisms Linking Intradialytic Circulatory Stress to Residual Renal Function Loss

NCT07003828End-Stage Renal Disease Requiring Haemodialysis

Yuanjun Yang

Observational

Beijing

2024-05-01

Recruiting

Partial Pressure of Oxygen Control Method in Identification of Intersegmental Plane

NCT06644066Lung Cancer

Tang-Du Hospital

Not applicable

Xi'an

2024-05-01

Recruiting

Renovated Prediction Model for Difficult Transoral and Submental Endoscopic Thyroidectomy

NCT06738888Thyroid Cancer, Thyroid Diseases, Thyroid Nodule

Shanghai 6th People's Hospital

Observational

300

Shanghai

2024-05-01

By invitation

Personalized Brain Stimulation for Cognitive Impairment in Older Adults

NCT07208734Alzheimer s Disease

Xuanwu Hospital, Beijing

Not applicable

460

Beijing

2024-05-01

Recruiting

Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

NCT06367088Triple-negative Breast Cancer, Cadonilimab

DrugCadonilimab

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2

Wuhan

2024-05-01

Recruiting

An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).

NCT06339060Esophageal Cancer

Ruijin Hospital

Phase 3

356

Shanghai

2024-05-01

Recruiting

the Multi-modal Evaluation of Agitation in Critically Ill Patients Based on Remote Video-Ultra-sensitive Detection Wave

NCT06543602Critically Ill Patients

Second Affiliated Hospital, Zhejiang University, School of Medicine

Observational

580

Hangzhou, Hanzhou

2024-05-01

Not yet open

Screening for Gaucher Disease and Acid Sphingomyelinase Deficiency

NCT06258577Gaucher Disease

Chung-Hsing Wang

Observational

2024-05-01

Recruiting

A Functional Near- Infrared Spectroscopy Study on the Brain Activation Characteristics of Stroke Patients During Mirror Movement

NCT07509944Stroke, Upper Limb Function

Second Affiliated Hospital, Zhejiang University, School of Medicine

Observational

Hangzhou

2024-05-01

Recruiting

Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Patients With Disorders of Consciousness

NCT07284732Disorders of Consciousness

Zhujiang Hospital

Not applicable

Guangzhou

2024-05-01

Recruiting

Effect of Ketosteril on Sarcopenia in Patients With Chronic Kidney Disease

NCT06329622Chronic Kidney Disease, Sarcopenia

Huashan Hospital

Phase 3

Shanghai

2024-05-01

Active, closed

Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer

NCT06419673Cervical Cancer

DrugsSerplulimab·Cisplatin·Carboplatin

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

240

Beijing

2024-05-01

Recruiting

Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

NCT06397222Hepatocellular Carcinoma Non-resectable

Second Affiliated Hospital of Guangzhou Medical University

Phase 2

Guangzhou

2024-05-01

Recruiting

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

NCT06397235Hepatocellular Carcinoma Non-resectable

DrugHAIC

Second Affiliated Hospital of Guangzhou Medical University

Phase 2

130

Guangzhou

2024-05-01

Recruiting

Cervical Cancer Susceptible Population Classification

NCT06405945Cervical Cancer Susceptible Population Classification

Anhui Provincial Hospital

Observational

10,000

Hefei

2024-05-01

Recruiting

Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer

NCT06728878Gastric Cancers

Jichao Qin

Observational

150

Hangzhou

2024-05-01

Recruiting

A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma

NCT06497738Multiple Myeloma

The First Affiliated Hospital with Nanjing Medical University

Observational

112

Changzhou, Nanjing, Nantong, Taizhou, Yancheng

2024-05-01

Recruiting

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

NCT06379087Non-Small Cell Lung Cancer

DrugsAnlotinib hydrochloride·Anlotinib·Tislelizumab

Ji Yongling

Phase 2

Hangzhou

2024-05-01

Recruiting

Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC

NCT06456515Colorectal Cancer Metastatic

The First People's Hospital of Changzhou

Not applicable

Changzhou

2024-05-01

Recruiting

Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy

NCT06728891Gastric Carcinoma

Jichao Qin

Observational

100

Hangzhou

2024-05-01

Not yet open

Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC

NCT06346808Pancreatic Cancer

Sichuan University

Phase 1

Chengdu

2024-05-01

Recruiting

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

NCT06361589ALK-positive Non-small Cell Lung Cancer, Real World Study

DrugLorlatinib

Sichuan Cancer Hospital and Research Institute

Observational

200

Chengdu

2024-05-01

Not yet open

Screening for High-risk Chronic Obstructive Pulmonary Disease

NCT06350305High-risk COPD

Henan University of Traditional Chinese Medicine

Observational

3,600

Zhengzhou

2024-05-01

Recruiting

Multicenter Cohort Study of ESD and Chemo-radiotherapy for High-risk Early-stage Esophageal Cancer

NCT06385717Esophagus Cancer

Second Affiliated Hospital, Zhejiang University, School of Medicine

Observational

120

Hangzhou

2024-05-01

Recruiting

Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric Cancer

NCT06736847Gastric Carcinoma

Jichao Qin

Observational

200

Hangzhou

2024-05-01

Not yet open

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT06254599Non-small Cell Lung Cancer

DrugCrizotinib

Shouyao Holdings (Beijing) Co. LTD

Phase 3

255

Beijing

2024-05-01

Recruiting

Effects of Aromatherapy on Anxiety and Pain During Dental Treatment in Adults

NCT06347679Dental Anxiety

Sichuan University

Not applicable

120

Chengdu

2024-05-01

Recruiting

Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer

NCT06395844Ovarian Cancer

Anhui Provincial Cancer Hospital

Phase 1/2

Hefei

2024-05-01

Recruiting

Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer

NCT06368141Colon Cancer

DrugsSerplulimab·Capecitabine·Oxaliplatin

Ruijin Hospital

Phase 2

Shanghai

2024-05-01

Not yet open

Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer

NCT05707468Oligometastatic Prostate Carcinoma

DrugAbiraterone

Changhai Hospital

Not applicable

200

Guangzhou, Suzhou, Wuxi, Ningbo, Shanghai

2024-05-01

Not yet open

KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial

NCT06370026Nasopharyngeal Carcinoma

DrugKSD-101

Sun Yat-sen University

Early Phase 1

Guangzhou

2024-05-01

Recruiting

Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

NCT06575257Prostate Cancer

DrugsGoserelin·Darolutamide

Xijing Hospital

Phase 2

Xi’an

2024-05-01

Recruiting

Narlumosbartmab Combined With Neoadjuvant Chemotherapy in Bone-derived Malignancies With Osteolytic Lesions and Multinucleated Giant Cells

NCT06302465Malignant Bone Tumor

Peking University People's Hospital

Not applicable

Beijing

2024-05-01

Active, closed

Pallidothalamic Tracts Electrical Stimulation for Lennox-Gastaut Syndrome

NCT06464653Lennox Gastaut Syndrome

Liankun_Ren

Not applicable

Beijing

2024-05-01

Recruiting

Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer

NCT06405139Colorectal Cancer

DrugCapecitabine

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2024-05-01

Active, closed

A Machine Learning-based Estimated Survival Model

NCT06432283Advanced Solid Tumor

Zhao Siyao

Observational

1,000

Chengdu

2024-05-01

Not yet open

PK/PD Study of Anti-Infective Drugs in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation Treatment

NCT06319677Critical Illness, Extracorporeal Membrane Oxygenation Complication

The Third Xiangya Hospital of Central South University

Observational

Changsha

2024-05-01

Recruiting

Micro-movements in Patients With Prolonged Disorders of Consciousness

NCT06406413Consciousness Disorders

First Affiliated Hospital of Zhejiang University

Observational

179

Hanzhou

2024-05-01

Recruiting

Intestinal Flora and Immunity in Monoclonal Gammopathy Patients

NCT06539832Multiple Myeloma, MGUS, Gut Microbiota, Infections

Zhujiang Hospital

Observational

300

Guanzhou

2024-05-01

Not yet open

Concomitant Tricuspid Repair in Patients With Left Heart Surgery

NCT05595187Tricuspid Regurgitation, Mitral Regurgitation, Cardiopulmonary Bypass

Nanjing Medical University

Not applicable

400

Nanjing

2024-05-01

Recruiting

Single-operator Versus Two-operator Technique in Single-balloon Enteroscopy

NCT06280469Single-balloon Enteroscopy, Operation

Shuhui Liang

Not applicable

228

Lanzhou, Zhuhai, Xi'an

2024-05-01

Recruiting

Whole Genome Sequencing Versus Whole Exome Sequencing for Congenital Diarrhea and Enteropahty

NCT04528303Diarrhea, Infantile, Enteropathy

Children's Hospital of Fudan University

Not applicable

180

Shanghai

2024-05-01

By invitation

Based on the Data from the Zhejiang Emergency Center, Explore the Independent and Interactive Effects of the Association Between Meteorological Factors and Air Pollution and the Number of Emergency Personnel, Identify the Relevant Vulnerable Population Characteristics, Sensitive Disease Types

NCT06798987Fig. Impetuous

Li hengjie

Observational

1,500,000

Hangzhou

2024-05-01

Active, closed

N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy

NCT07279610Thrombotic Microangiopathy

The First Affiliated Hospital of Soochow University

Phase 2/3

Suzhou

2024-05-01

Active, closed

A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab

NCT06681298Adenocarcinoma of the Esophagogastric Junction, Perioperative Period

DrugsFLOT·Trastuzumab

xiaohua li

Phase 2

Xi'an

2024-05-01

Recruiting

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

NCT06384352Advanced Solid Tumors

DrugsPemetrexed·Cisplatin·Carboplatin·Pembrolizumab

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1

500

Beijing, Hangzhou, Wenzhou, Chengdu, Guangzhou

2024-05-01

Not yet open

A Study on Factors of Biochemical Response in Autoimmune Hepatitis

NCT06356506Autoimmune Hepatitis

Beijing Friendship Hospital

Observational

630

Beijing

2024-05-01

Recruiting

Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis

NCT06389422Hepatocellular Carcinoma, Radiotherapy, Pembrolizumab, Tumor Thrombosis

DrugPembrolizumab

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2024-05-01

Not yet open

Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

NCT06409429Pancreatic Cancer

DrugNimotuzumab

Tianjin Medical University Cancer Institute and Hospital

Phase 2/3

146

Tianjin

2024-05-01

Recruiting

Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients

NCT06404697Breast Cancer

Ruijin Hospital

Phase 2

Shanghai

2024-05

Recruiting

Application of Machine Learning Based on fNIRS in Predicting Acupuncture's Efficacy in Treating Tinnitus

NCT06364670Tinnitus

The Third Affiliated hospital of Zhejiang Chinese Medical University

Not applicable

500

Hangzhou

2024-05

Not yet open

Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke

NCT06374823Critical Care, Hyperchloremia, Hemorrhagic Stroke

Capital Medical University

Phase 4

342

Beijing

2024-05

Not yet open

To Evaluate the Efficacy and Safety of an Defocus Lens in Slowing the Progression of Myopia

NCT06405711Myopia, Progressive

Tianjin Eye Hospital

Not applicable

138

Tianjin

2024-05

Recruiting

Effect and Mechanism of Baitouweng Decoction for Large Intestine Damp-heat Syndrome of Ulcerative Colitis

NCT06421818Ulcerative Colitis

The Second Hospital of Nanjing Medical University

Phase 2

144

Nanjing

2024-05

Not yet open

Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer

NCT06423937Colorectal Cancer

DrugCamrelizumab

Fudan University

Phase 2

129

Shanghai

2024-05

Not yet open

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

NCT06370754Pancreatic Cancer

DrugsJS015·JS007·Tifcemalimab·Irinotecan liposome

Fudan University

Phase 1/2

117

Shanghai

2024-04-30

Recruiting

The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study

NCT06958627HER2 Positive Breast Cancer, Pyrotinib Treatment

DrugPyrotinib

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2/3

964

Beijing

2024-04-30

Recruiting

Exploring the Possible Beneficial Impact of Non-invasive and Invasive Neuromodulation on Freezing of Gait in Parkinson's Disease During Different Ambulatory Complexities: An Electrophysiological and fMRI Study

NCT06505460Transcranial Direct Current Stimulation

China Medical University Hospital

Not applicable

2024-04-30

Recruiting

To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors

NCT06592417Advanced Malignant Solid Tumor

DrugJSKN016

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1

140

Fuzhou, Guangzhou

2024-04-30

Recruiting

Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer

NCT06518135Sentinel Lymph Node Biopsy

Henan Cancer Hospital

Observational

508

Henan

2024-04-30

Recruiting

Efficacy of Acupuncture for the Treatment of Parkinson's Disease Related Constipation

NCT06390761Parkinson Disease, Constipation, Non-motor Symptom, Randomized Controlled Trial

Xi'an No.3 Hospital

Not applicable

Xi'an

2024-04-30

Recruiting

The Effect of Morning vs Evening Aerobic Exercise Training on Cardiac Remodeling and Function Improvement in Patients After ST Elevation Myocardial Infarction

NCT06385834ST-segment Elevation Myocardial Infarction (STEMI)

RenJi Hospital

Not applicable

201

Shanghai

2024-04-30

Not yet open

Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma

NCT06396481GBM, DIPG Brain Tumor, Medulloblastoma

Beijing Tiantan Hospital

Early Phase 1

Beijing

2024-04-30

Recruiting

First-into-human Study of NS-136 in Healthy Subjects

NCT06345703Healthy Subjects

DrugNS-136

NeuShen Therapeutics

Phase 1

Chengdu

2024-04-30

Recruiting

Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer

NCT07635342HER2-positive Breast Cancer

DrugsPaclitaxel （Albumin Bound）·Pyrotinib Maleate·Pegylated liposomal doxorubicin·Cyclophosphamide

Hebei Medical University Fourth Hospital

Phase 2

182

Shijiazhuang

2024-04-30

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097Non-small Cell Lung Cancer

DrugsDato-DXd·Osimertinib

AstraZeneca

Phase 3

582

Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin

2024-04-29

Recruiting

Intratonsillar Immunotherapy for Allergic Rhinitis

NCT06523478Allergic Rhinitis

Xu Yu

Not applicable

120

Wuhan

2024-04-29

Recruiting

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

NCT06539182Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

DrugBirelentinib

Dizal Pharmaceuticals

Phase 2

155

Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun, Dalian

2024-04-29

Recruiting

A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b

NCT06217861Glutaric Acidemia Type I, Glutaric Aciduria Type I

Shanghai Vitalgen BioPharma Co., Ltd.

Phase 1

Hangzhou

2024-04-29

Recruiting

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

NCT06389006Breast Cancer

DrugsJS001·Epirubicin·Disitamab Vedotin·Toripalimab

RemeGen Co., Ltd.

Phase 2

Shanghai

2024-04-29

Recruiting

Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke

NCT06045156Acute Ischemic Stroke

DrugTirofiban

The First Hospital of Jilin University

Not applicable

1,084

Changchun

2024-04-29

Recruiting

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugLebrikizumab

Eli Lilly and Company

Phase 3

510

Beijing, Bengbu, Changsha, Chengdu, Foshan, Fuzhou, Guangdong, Haikou

2024-04-29

Not yet open

A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

NCT06387420ACUTE MYELOID LEUKEMIA; AML

DrugsLigufalimab·Azacitidine·Venetoclax

Akeso

Phase 1/2

180

Tianjin

2024-04-29

Recruiting

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

NCT06385925Malignant Neoplasm

DrugsFluorouracil·Leucovorin·Oxaliplatin

Tyligand Pharmaceuticals (Suzhou) Limited

Phase 1/2

440

Hefei, Beijing, Guangzhou, Wuhan, Changsha, Nanchang, Linyi, Shanghai

2024-04-29

Active, closed

Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer

NCT06394661Breast Cancer

DrugsNabPE·Serplulimab

Henan Cancer Hospital

Phase 2

109

Henan

2024-04-28

Recruiting

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage

NCT06376474Psoriasis

DrugMufemilast

Ganzhou Hemay Pharmaceutical Co., Ltd

Phase 1

Wuhan

2024-04-28

Recruiting

Washed Microbiota Transplantation for Attention-deficit/Hyperactivity Disorder

NCT06376331Attention-deficit/Hyperactivity Disorder

DrugWashed Microbiota Transplantation

The Second Hospital of Nanjing Medical University

Observational

Nanjing

2024-04-28

Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961End Stage Kidney Disease

DrugClazakizumab

CSL Behring

Phase 2/3

3,110

Baotou Shi, Beijeing, Beijing, Chengdu, Dalian, Deyang Shi, Dongguan, Foshan Shi

2024-04-27

Recruiting

The Epidemiological and Intrinsic Characteristics of Chronic Rhinitis

NCT06370468Chronic Rhinitis

Zheng Liu ENT

Observational

150,000

Wuhan

2024-04-27

Recruiting

3D Facial Scanning for Evaluating Autologous Fat Grafting in Craniofacial Deformities

NCT06306326Adipocytes, Autografts, Imaging, Three-Dimensional / Methods

Peking University

Not applicable

100

Beijing

2024-04-27

Recruiting

Cognitive Leisure and Preclinical Alzheimer's Disease: Exploring Neural Mechanisms

NCT06215274Cognitive Dysfunction

Yuanjiao Yan

Observational

156

Fuzhou

2024-04-27

Recruiting

Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.

NCT07437404Haemophilia A

Sinocelltech Ltd.

Phase 3

Beijing

2024-04-26

Recruiting

Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands

NCT06685978Hyperplasia of Mammary Glands

Tasly Pharmaceutical Group Co., Ltd

Phase 3

430

Beijing, Chongqing, Xiamen, Guangzhou, Baoding, Cangzhou, Shijiazhuang, Daqing

2024-04-26

Recruiting

A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

NCT06387069Acute Myeloid Leukemia

DrugHMPL-306

Hutchmed

Phase 3

316

Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Guanzhou

2024-04-26

Recruiting

Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

NCT06298968Intrahepatic Cholangiocarcinoma

Nanfang Hospital, Southern Medical University

Phase 2

Guangzhou

2024-04-26

Active, closed

A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC

NCT06383052Metastatic Castration-resistant Prostate Cancer

Norroy Bioscience Co., LTD

Phase 1/2

Wuxi

2024-04-26

Recruiting

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

NCT06332170Advanced Solid Tumor

DrugsRis-Rez·Cisplatin/Carboplatin·Enzalutamide·Adebrelimab

Hansoh BioMedical R&D Company

Phase 1

610

Shanghai

2024-04-26

Active, closed

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

NCT06339008Perennial Allergic Rhinitis (PAR)

DrugLebrikizumab

Eli Lilly and Company

Phase 3

450

Beijing, Changsha, Guangzhou, Hangzhou, Jingzhou, Nanchang, Nanning, Shanghai

2024-04-26

Recruiting

Autologous Non-cultured Epidermal Cell Suspension Transplantation in the Treatment of Vitiligo

NCT07187882Vitiligo

Peking University People's Hospital

Not applicable

Beijing

2024-04-25

Recruiting

Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

NCT06393985B-cell Acute Lymphoblastic Leukemia

The First Affiliated Hospital of Soochow University

Phase 2

Suzhou

2024-04-25

Recruiting

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

NCT06431685NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor, Leptomeningeal Metastasis

DrugsSintilimab·Pemetrexed

Sichuan University

Phase 1

Chengdu

2024-04-25

Recruiting

A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

NCT06403735Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor

Qilu Pharmaceutical Co., Ltd.

Phase 1

250

Guangzhou, Harbin, Nanchang, Shanghai, Kunming

2024-04-25

Recruiting

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

NCT06445517Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma

InSilico Medicine Hong Kong Limited

Phase 1

Beijing, Nanchang, Shanghai, Tianjin

2024-04-25

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-china?page=27

Query this register directly

GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 07 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in China?

11,790 of the 19,187 studies in this register are recruiting new participants as of the 07 Nov 2026, 03:17 UTC sync. A further 3,998 have not yet opened recruitment, 2,715 are active but closed to new participants, and 684 are enrolling by invitation only. Eligibility for any study is decided by its study team.

→

Browse trials by condition

Breast Cancer (423) Advanced Solid Tumors (187) Colorectal Cancer (179) Gastric Cancer (175) Hepatocellular Carcinoma (154) Advanced Solid Tumor (153) Non-Small Cell Lung Cancer (145) Solid Tumor (142) Acute Ischemic Stroke (140) Lung Cancer (135) Non-small Cell Lung Cancer (132) Pancreatic Cancer (131) Multiple Myeloma (128) Coronary Artery Disease (122) Prostate Cancer (110)

→

Browse trials by site location

Beijing (5576) Shanghai (3879) Guangzhou (3345) Hangzhou (1819) Wuhan (1343) Chengdu (1307) Nanjing (1211) Changsha (1154) Chongqing (1078) Fuzhou (1040) Tianjin (934) Zhengzhou (931) Hefei (896) Jinan (783) Changchun (639)

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.